1	Longitudinal Analysis Over Decades Reveals the Development and Immune Implications
2	of Type I Interferon Autoantibodies in an Aging Population
3	
4	Sonja Fernbach ^{a,†} , Nina K. Mair ^{a,†} , Irene A. Abela ^{a,b} , Kevin Groen ^a , Roger Kuratli ^a , Marie Lork ^a ,
5	Christian W. Thorball ^c , Enos Bernasconi ^d , Paraskevas Filippidis ^e , Karoline Leuzinger ^f , Julia
6	Notter ^g , Andri Rauch ^h , Hans H. Hirsch ⁱ , Michael Huber ^a , Huldrych F. Günthard ^{a,b} , Jacques
7	Fellay ^{c,j} , Roger D. Kouyos ^{a,b} , Benjamin G. Hale ^{a,*} , and The Swiss HIV Cohort Study
8	
9	^a Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
10	^b Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
11	University of Zurich, Zurich, Switzerland.
12	^c Precision Medicine Unit, Lausanne University Hospital and University of Lausanne, Lausanne,
13	Switzerland.
14	^d Division of Infectious Diseases, Ente Ospedaliero Cantonale Lugano, University of Geneva and
15	University of Southern Switzerland, Lugano, Switzerland.
16	^e Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and
17	University of Lausanne, Lausanne, Switzerland.
18	^f Clinical Virology, University Hospital Basel, Basel, Switzerland.
19	^g Division of Infectious Diseases, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
20	^h Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern,
21	Bern, Switzerland.
22	ⁱ Transplantation and Clinical Virology, Department of Biomedicine, University of Basel, Basel,
23	Switzerland.
24	^j School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
25	
26	[†] These authors contributed equally to this work and are listed alphabetically.

27	
28	*Corresponding author: <u>hale.ben@virology.uzh.ch</u> ; 0000-0002-3891-9480 (ORCID).
29	
30	Running title: Development and consequences of IFN-I autoAbs
31	Character count: 38,057 (not including spaces, figure legends, methods, or references)
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	

53

ABSTRACT

54

55 Pre-existing autoantibodies (autoAbs) neutralizing type I interferons (IFN-Is: IFN α , IFN β , IFN ω) 56 have recently been described as significant contributors to the severity of viral infectious 57 diseases. Here, we explore the development and consequences of anti-IFN-I autoAbs at high-58 resolution using retrospective samples and data from 1876 well-treated individuals >65 years of 59 age enrolled in the Swiss HIV Cohort Study, a nationwide, longitudinal cohort with up to 35 years 60 of follow-up. Approximately 1.9% of individuals developed anti-IFN-I autoAbs, with a median 61 onset age of ~63 years (range 45-80). Once developed, anti-IFN-I autoAbs persisted for life, and 62 generally increased in titer over years. Most individuals developed distinct neutralizing and non-63 neutralizing anti-IFN-I autoAb repertoires at discrete times that selectively targeted various 64 combinations of IFN α , IFN β , and IFN ω . Longitudinal analyses further revealed that emergence 65 of neutralizing anti-IFNa autoAbs correlated with reduced IFN-stimulated gene (ISG) levels, 66 indicating impairment of innate immunity. Patient data review suggested that prior recorded viral 67 infections and autoimmune history influence the likelihood of mounting anti-IFN-I autoAbs. 68 Indeed, systematic measurements in biobanked samples revealed significant enrichment of pre-69 existing autoreactivity against clinically relevant autoantigens in individuals who later developed 70 anti-IFN-I autoAbs. In this context, we describe lifelong neutralizing anti-IFNa autoAbs (and 71 impaired innate immunity), that manifested in an individual following IFN α therapy, and who was 72 retrospectively found to have had pre-existing autoreactivity to β2-glycoprotein-I before IFNa 73 treatment. Our decades-spanning longitudinal analyses illuminate the development and immune 74 implications of anti-IFN-I autoAbs in an aging population, and support a 'two-hit' hypothesis 75 whereby loss of self-tolerance prior to immune-triggering with endogenous or exogenous IFN-I 76 may pose a risk for developing late-onset, lifelong IFN-I functional deficiency.

77

78

INTRODUCTION

79

80 Deficiencies in the human type I interferon (IFN-I) system leave individuals susceptible to a 81 range of severe viral diseases typically caused by pathogens to which they lack pre-existing 82 humoral immunity (reviewed in (Duncan et al., 2021; Meyts and Casanova, 2021; Stertz and 83 Hale, 2021)). While life-threatening viral diseases linked directly to genetic defects in the IFN-I 84 system are extremely rare (and mainly manifest themselves in the very young) (Duncan et al., 85 2021), it has recently become apparent from cross-sectional studies that a functional defect 86 caused by autoantibodies (autoAbs) targeting IFN-I cytokines is not particularly rare in elderly 87 populations (reviewed in (Bastard et al., 2024a; Hale, 2023)). Specifically, the prevalence of 88 autoAbs neutralizing the IFN-I cytokines IFN α and/or IFN ω increases sharply with age in 89 otherwise healthy individuals, such that a conservative estimate of prevalence in those >70 90 years old is about eight times higher (1.4%) than that in younger individuals (0.17%) (Bastard et 91 al., 2021). Furthermore, the presence of neutralizing anti-IFN-I autoAbs in individuals has been 92 associated with an increased susceptibility to severe infections caused by several viral 93 pathogens, including SARS-CoV-2 (Akbil et al., 2022; Bastard et al., 2024b; Bastard et al., 2020; 94 Busnadiego et al., 2022; Chauvineau-Grenier et al., 2022; Credle et al., 2022; Eto et al., 2022; 95 Frasca et al., 2022; Goncalves et al., 2021; Manry et al., 2022; Mathian et al., 2022; Scordio et 96 al., 2022; Solanich et al., 2021; Troya et al., 2021; Wang et al., 2021), MERS-CoV (Alotaibi et 97 al., 2023), influenza A virus (Zhang et al., 2022), West Nile virus (Gervais et al., 2023; Lin et al., 98 2023), and various herpesviruses (Bayat et al., 2015; Burbelo et al., 2010; Busnadiego et al., 99 2022; Hetemaki et al., 2021; Mathian et al., 2022; Mogensen et al., 1981; Pozzetto et al., 1984). 100 Given that more than 100 million people worldwide have been estimated to potentially harbor 101 neutralizing anti-IFN-I autoAbs (Bastard et al., 2024a), and are therefore at increased risk of 102 severe infectious disease outcomes, it is critical to understand factors associated with their 103 development and pathogenic mechanisms in order to inform future mitigation strategies.

104

105 Multiple distinct host genetic defects converging on disruption of central T-cell tolerance in the 106 thymus have been shown to underlie the development of anti-IFN-I autoAbs in several patient 107 cohorts (reviewed in (Bastard et al., 2024a; Hale, 2023)). The best characterized examples of 108 these defects include mutations in the AIRE gene, which encodes an autoimmune regulator that 109 normally ensures negative selection of autoreactive T-cells (Meager et al., 2006; Meyer et al., 110 2016), and mutations in the NFKB2, MAP3K14 (NIK) and RELB genes, that encode components 111 of the alternative NF- κ B pathway and regulate AIRE expression (Bodansky et al., 2022; Le 112 Voyer et al., 2023; Ramakrishnan et al., 2018; Sjogren et al., 2022). Patients with these genetic 113 defects exhibit thymic abnormalities and reduced self-tolerance, and typically develop anti-IFN-I 114 autoAbs in early childhood (Le Voyer et al., 2023; Meager et al., 2006), which has been 115 speculated to occur following an infection event triggering 'immunization' with endogenous IFN-I 116 (Hale, 2023). However, the role of genetics and other pre-disposing factors in contributing to the 117 increased prevalence of anti-IFN-I autoAbs in elderly populations is little understood, and it still 118 remains to be resolved at the individual level at what point in life these autoAbs develop, their 119 longevity, and their impact on an individual's innate antiviral defenses. Furthermore, associations 120 between potential 'immunization' events, such as infections, and the development of anti-IFN-I 121 autoAbs have yet to be investigated. These gaps in our knowledge mainly result from a lack of 122 available longitudinal samples and lack of systematic clinical histories taken from before anti-123 IFN-I autoAbs developed in individuals, as well as the limited time that has passed so far for 124 patients recently identified to harbor anti-IFN-I autoAbs, which has prevented long-term follow-up 125 studies.

126

Here, we sought to leverage the Swiss HIV Cohort Study (SHCS) as a large nationwide, systematic, longitudinal infectious disease cohort to study the development and consequences of anti-IFN-I autoAbs in elderly individuals. The SHCS was founded in 1988, and contains

130 historic, semiannually biobanked plasma and cell samples, as well as clinical data, from more 131 than 21,000 people living with HIV (PLH) over the course of 35 years (Scherrer et al., 2022). 132 With improved success of long-term antiretroviral therapy, life-expectancy in this cohort is now 133 approaching that of the general population in Switzerland (Gueler et al., 2017). Thus, this well-134 treated cohort is aging, and individuals >50 years of age make up around 60% of the currently 135 enrolled patients, with most having been followed-up for almost half their adult lives. 136 Furthermore, IFN-I therapy was widely used in this cohort for hepatitis C virus (HCV) treatment 137 before directly acting antivirals became available (Baumann et al., 2024). Using this resource, 138 we wanted to track the levels of neutralizing and non-neutralizing anti-IFN-I autoAb repertoires 139 (targeting IFN α , IFN β , and IFN ω) in individuals over decades at high-resolution, thus providing 140 key information on the timing of autoAb induction and their longevity. Furthermore, we aimed to 141 describe the impact of neutralizing anti-IFN-I autoAbs on innate antiviral defenses, and to 142 perform exploratory analyses of clinical record data to investigate whether pre-disposing factors 143 or events influence the likelihood of anti-IFN-I autoAb development.

- 144
- 145

RESULTS

146

147 Identification and characterization of anti-IFN-I autoAbs in an aging, longitudinally 148 sampled, infectious disease patient cohort.

To systematically investigate the age-related development of anti-IFN-I autoAbs in the SHCS, we initially selected recent plasma samples taken from a sub-cohort of 1876 well-treated individuals >65 years of age (82% male, median year of birth 1949, IQR 1943-1954; **Supplementary Table 1**). Age and sample availability were the only criteria considered in this selection. We then applied a multiplexed bead-based assay to screen these samples for IgG autoAbs binding to the representative type I IFNs: IFN α 2, IFN β and IFN ω . Samples identified to be positive were subsequently tested for neutralization capacity against the respective IFN-I at

156 different doses. We observed that 0.85% of individuals (16/1876) had neutralizing autoAbs 157 against IFN α 2, 0.32% of individuals (6/1876) had neutralizing autoAbs against IFN β , and 0.48% 158 of individuals (9/1876) had neutralizing autoAbs against IFN ω (Fig. 1A). Overall, 1.17% of the 159 individuals in our >65 cohort (22/1876) had neutralizing autoAbs against at least one IFN-I, a 160 prevalence similar to that noted previously in similarly-aged, otherwise healthy, individuals 161 (Bastard et al., 2021). An additional 0.69% of individuals in our >65 sub-cohort (13/1876) had 162 detectable anti-IFN-I autoAbs that were non-neutralizing (0.11% IFN α 2, 0.21% IFN β and 0.48% 163 IFNw). With regards patient ethnicity, most likely source of HIV-1 infection, and baseline levels 164 of HIV-1 RNA, there were no clear differences between those with detectable levels of anti-IFN-I 165 autoAbs compared to those without (Supplementary Table 1). However, males made up 94.3% 166 (33/35) of those identified to have anti-IFN-I autoAbs as compared to 81.9% (1507/1841) of 167 males in the population without anti-IFN-I autoAbs, suggesting a trend towards increased 168 prevalence in males (Supplementary Table 1). Notably, one individual (P5) had IgG autoAbs 169 binding and neutralizing all three type I IFNs, while most had binding autoAbs specific for IFN α 2 170 (0.53%, 10/1876), IFNω (0.43%, 8/1876), or both IFNα2 and IFNω (0.37%, 7/1876) (Figs. 1B & 171 1C). Seven individuals (0.37%) only had IgG autoAbs specific to IFNB, while two individuals 172 (0.11%) had IgG autoAbs against IFNβ and IFNω (Figs. 1B & 1C). While most anti-IFN-I 173 autoAb-positive plasmas neutralized the respective IFN-I, it was striking that the majority of 174 plasmas positive for anti-IFN_w autoAbs alone appeared to be non-neutralizing at the plasma 175 dilution tested (Fig. 1C). Further characterization of each individual's anti-IFN-I IgG autoAb 176 subclasses revealed a binding antibody response dominated by IgG1 autoAbs in most 177 individuals (Figs. 1D & 1E). However, it was interesting to observe that IgG4 was also a 178 commonly identified subclass of anti-IFN α 2 and anti-IFN ω IgG autoAbs (statistically significant 179 for IFN α 2, but not for IFN ω), and that IgG4 even dominated in a few individuals with these types 180 of autoAbs. In contrast, it was notable that anti-IFNß IgG4 did not dominate in any individual 181 (Fig. 1E). Anti-IFN-I IgG autoAbs of the IgG3 subclass were also sporadically detected, and

represented the main IgG autoAb in some individual patients, while anti-IFN-I IgG2 autoAbs were very rarely detected or of low titer (**Figs. 1D & 1E**). Thus, the anti-IFN-I IgG autoAb landscape in our sub-cohort is mostly comprised of the IgG1 subclass. Overall, our screening data reveal the diversity of anti-IFN-I autoAbs in a sub-cohort of PLH individuals >65 years of age, and indicate that the prevalence of these autoAbs in this sub-cohort (1.17% for neutralizing autoAbs only) is highly comparable to that previously reported in a similarly-aged healthy cohort (Bastard et al., 2021).

189

High-resolution longitudinal analysis of anti-IFN-I autoAb levels reveals their acute age associated development and persistence over decades.

192 For all 35 anti-IFN-I autoAb positive individuals, as well as for 35 anti-IFN-I autoAb negative 193 individuals (matched for sex and year of birth), we obtained historic biobanked plasma samples 194 from all timepoints available in the SHCS since enrollment. Samples were typically available 195 from two timepoints (approximately 6-monthly) per year, and spanned an average of 20.2 years 196 (range 9-27) for each anti-IFN-I autoAb positive individual. As an example, the anti-IFN-I autoAb 197 positive individual with the most samples available had 52 plasma samples that were taken 198 between the ages of 43 and 70 (i.e. over a 27-year period). For all longitudinal plasma samples 199 we assessed levels of IgG autoAbs binding to each type I IFN, and subsequently tested most 200 samples for IFN-I neutralization capacity, resulting in a temporal overview of anti-IFN-I autoAb 201 binding and neutralization development for each individual (Fig. 2 and Supplementary Fig. 1). 202 Despite individual heterogeneity with regard to anti-IFN-I autoAb reactivity, several common 203 features were apparent from analyzing the anti-IFN-I autoAb positive population. Firstly, for 204 34/35 anti-IFN-I autoAb positive individuals, anti-IFN-I autoAbs were undetectable for many 205 years in the available samples prior to the occurrence of a positive sample, indicating that the 206 autoAbs did not exist in these individuals for most of their lives. This is in stark contrast with patients harboring mutations in the AIRE gene or in genes of the alternative NF-kB pathway. 207

208 where anti-IFN-I autoAbs are detectable very early in childhood (Le Voyer et al., 2023; Meager 209 et al., 2006). Indeed, confirming the age-related onset of anti-IFN-I autoAbs in our study 210 population, the median ages of new-onset autoAb detection were remarkably similar, at 63, 63, 211 and 61.5 years for anti-IFN α 2, anti-IFN β , and anti-IFN ω , respectively, with a range of ages 212 spanning years 45-80 (Fig. 2A). Secondly, anti-IFN-I autoAbs first developed at a specific, 213 discrete timepoint in each individual, indicating that their induction was likely triggered by a 214 certain acute event. Thirdly, anti-IFN-I autoAbs generally increased in binding titers over time for 215 anti-IFN α 2 and anti-IFN ω , but not for anti-IFN β (Fig. 2B), which might reflect increases in 216 autoAb abundance or increases in avidity towards the IFN α 2 and anti-IFN ω antigens. However, 217 it is unclear why this appears to be antigen specific. Finally, with the exception of rare transient 218 'blips' at early timepoints (e.g. P8), it was apparent that the presence of anti-IFN-I autoAbs never 219 resolved, and once developed they persisted continuously in subsequent plasma samples (Figs. 220 2C-I and Supplementary Fig. 1). For example, the longest duration of neutralizing anti-IFN-I 221 autoAbs detected in our study sub-cohort was approximately 15 years (P12 and P32; Fig. 2D), 222 and 11 individuals maintained anti-IFN-I autoAbs for at least 10 years each. On the contrary, 223 anti-IFN-I binding autoAbs were never detected at any timepoint in the 35 negative individuals 224 tested longitudinally (see examples in Fig. 21 and Supplementary Fig. 2). Overall, our 225 longitudinal data reveal acute induction of anti-IFN-I autoAbs that can occur in some individuals 226 around the age of 60-65 years, which is followed by subsequent lifelong maintenance of these 227 anti-IFN-I autoAbs.

228

Distinct individual variation in the timing and specificity of anti-IFN-I autoAb
 development.

We observed various phenotypes relating to anti-IFN-I autoAbs that were particular to certain individuals, or to groups of individuals. For example, it was striking in the single individual with autoAbs binding and neutralizing all three type I IFNs (P5) (**Fig. 2C**) that each anti-IFN-I autoAb

234 developed at different times over the course of seven years, with anti-IFNa2 autoAbs developing 235 after age 55, anti-IFN β autoAbs developing after age 61, and anti-IFN ω autoAbs developing 236 after age 62. This suggests that different acute events might have triggered development of 237 these different neutralizing autoAb reactivities at different times. A similar pattern was observed 238 in individual P32, who developed neutralizing anti-IFN α 2 autoAbs after age 55, followed by 239 neutralizing anti-IFN ω autoAbs around age 60 (Fig. 2D). However, anti-IFN β autoAbs never 240 developed in P32, highlighting inter-individual variability in the types of IFN-I antigens to which 241 anti-IFN-I autoAbs can be raised. While reactivity to both IFN α 2 and IFN ω was not uncommon to 242 observe (7/35 individuals; Figs. 2D and 2G) there were many examples where reactivity to 243 either only IFN α 2 (10/35 individuals; e.g. Fig. 2F and Supplementary Fig. 1C) or IFN ω (8/35 244 individuals; Supplementary Figs. 1B and 1E) occurred, indicating that specificity of reactivity at 245 the individual level, even between these two closely related type I IFNs, is possible despite the 246 known potential for IFN α /IFN ω cross-reactive autoAbs to exist (Meyer et al., 2016). Furthermore, 247 such lack of reactivity to both IFN α 2 and IFN ω was not simply a consequence of short time 248 periods preventing the broadening of reactivity from one IFN to the other, as some individuals 249 had specific anti-IFN α 2 or anti-IFN ω autoAbs for 8 years (P4, P21; Fig. 2F and Supplementary 250 Fig. 2C), 11 years (P7), or even 15 years (P10; Supplementary Fig. 2E) without developing 251 autoAbs against the other IFN. In a similar specificity example, individual P6 developed anti-252 IFNω autoAbs after the age of 80 and then developed anti-IFNβ autoAbs after the age of 82, but 253 never developed anti-IFNα2 autoAbs (Fig. 2E). Thus, even within 35 individuals, almost all 254 combinations of anti-IFN-I autoAb reactivities could be observed, which also extended to 255 variations of whether the autoAbs were able to neutralize the action of IFN-I or not. Overall, our 256 longitudinal analyses reveal that neither time of induction, binding specificity, nor neutralization 257 capacity of anti-IFN-I autoAb repertoires can be generalized, but probably reflect distinct host or 258 environmental factors specific to each individual.

259

Development of neutralizing anti-IFNα2 autoAbs is associated with compromised baseline IFN-stimulated gene levels.

262 Our production of high-resolution longitudinal anti-IFN-I autoAb binding and neutralization data in a highly-studied infectious disease cohort, combined with the availability of biobanked samples 263 264 and clinical data spanning multiple decades, gave us the possibility to dissect consequences of 265 anti-IFN-I autoAb development in individual patients. Given the heterogeneity of types of anti-266 IFN-I autoAbs observed in our sub-cohort, we focused studies on individuals who developed 267 neutralizing anti-IFNα2 autoAbs, with the rationale that this was the largest 'homogeneous' sub-268 group (n=16), and that neutralization capacity was most likely to have explainable functional 269 consequences. We began by looking at the consequences of anti-IFN-I autoAb development on 270 well-documented database-recorded outcomes related to HIV-1 viral loads and consequences, 271 incidences of other viral infections (e.g. herpes zoster, HSV-1 and CMV), bacterial and fungal 272 infections, and outcomes such as diabetes or cancers. For each individual, we analyzed these 273 outcomes for their whole lifetime following first detection of neutralizing anti-IFNa2 autoAbs, and 274 compared the results to anti-IFN-I autoAb negative individuals within the SHCS database who 275 were matched for sex, registration date, study center, and year of birth (n=62). We did not 276 observe a significant effect of neutralizing anti-IFNa2 autoAbs on any of the recorded outcomes 277 (Supplementary Table 2) which, for HIV-1 at least, might reflect the high effectiveness of longterm antiretroviral therapy. Furthermore, at the cellular level, we did not observe that 278 279 development of neutralizing anti-IFNa2 autoAbs correlated with any changes to specific blood 280 cell compositions, including leukocytes, platelets, or various lymphocyte sub-populations (Fig. 281 **3A**). To investigate directly whether the development of neutralizing anti-IFN α 2 autoAbs had 282 consequences for IFN-stimulated gene (ISG) expression, we next analyzed baseline ISG levels 283 in multiple frozen biobanked PBMC samples that were available from 13 individuals who 284 developed neutralizing anti-IFNa2 autoAbs, as well as from 13 age-matched negative-control 285 individuals who never developed anti-IFN-I autoAbs. For each autoAb-positive individual, we

286 obtained 2-3 PBMC samples from timepoints before, and 2-3 PBMC samples from timepoints 287 after, autoAb development. In the case of negative-control individuals, we obtained a similar 288 number of samples from age-matched timepoints. Without culturing, total RNA was extracted 289 directly from frozen PBMCs and subjected to RT-qPCR analysis for a panel of 8 well-known ISG 290 mRNAs: MX1, RIGI, IRF9, RSAD2, IFITM3, IFIT2, IFIT3, and IFI44. As shown in Fig. 3B, mRNA 291 levels of all ISGs were significantly reduced in autoAb-positive individuals subsequent to their 292 development of neutralizing anti-IFNa2 autoAbs. In contrast, baseline ISG mRNA levels were 293 not reduced in autoAb-negative individuals at age-matched timepoints, and more than half of 294 these individuals actually exhibited increased levels of several ISGs over time (Fig. 3C). Overall, 295 these results build on previous cross-sectional descriptions of a correlation between neutralizing 296 anti-IFNα autoAbs and low ISG levels (Abers et al., 2021; Bastard et al., 2020; Kisand et al., 297 2008; Koning et al., 2021; Lopez et al., 2021; van der Wijst et al., 2021; Wang et al., 2021), and 298 reveal that age-associated development of neutralizing anti-IFNa2 autoAbs can have clear 299 temporal functional consequences, leading to compromised baseline ISG levels and thus 300 impaired innate antiviral responses.

301

302 **Prior virus infections may influence anti-IFN-I autoAb development.**

303 Beyond understanding the functional consequences of anti-IFN-I autoAbs, our longitudinal 304 dataset gave us the unique opportunity to probe the clinical records of each patient and to 305 understand factors potentially influencing the development of anti-IFN-I autoAbs. To do this, we 306 initially analyzed differences between our 35 anti-IFN-I autoAb positive patients and 138 autoAb 307 negative patients (matched for sex, registration date, study center, and year of birth) at all 308 timepoints that preceded first onset of anti-IFN-I autoAbs in positive individuals. Given the 309 matching for registration date and year of birth, the same timepoints could be considered for the 310 negative individuals. Out of 30 parameters investigated in an exploratory study, which were 311 either chosen due to their routine recording in the SHCS database or their infection-relatedness,

312 only prior CMV seropositivity and prior diagnosis of herpes zoster showed significant differences 313 between the two groups (Supplementary Table 3 and Figs. 4A-B). Notably, prior CMV 314 seropositivity had a small negative association with anti-IFN-I autoAb development (p=0.00696: Fig. 4A), suggesting a potential protective effect of CMV infection on anti-IFN-I autoAb 315 316 development. Indeed, CMV seropositivity has previously been reported to also negatively 317 associate with the development of multiple sclerosis (Sundqvist et al., 2014; Waubant et al., 318 2011), an autoimmune disease where heterogeneous pathogenic autoAbs may play important 319 roles (Höftberger et al., 2022). Thus, it could be that CMV persistence contributes to subtle 320 immunomodulatory changes to the host that reduce certain autoimmune responses in some 321 otherwise predisposed individuals.

322

323 Our analyses also showed that prior herpes zoster events had a small positive association with 324 anti-IFN-I autoAb development (p=0.01466; Fig. 4B). This was particularly surprising, as further 325 temporal analysis revealed that the prior recorded herpes zoster diagnoses did not always 326 immediately precede the onset of anti-IFN-I autoAb development, as might be expected if the 327 severe acute disease itself triggered autoAb production. Specifically, out of the 12 individuals 328 who developed anti-IFN-I autoAbs and had documented prior herpes zoster, only two individuals 329 (P10 and P24) had herpes zoster in the six months prior to first detection of anti-IFN-I autoAbs. 330 Of the remaining 10 individuals, the herpes zoster events were recorded variously between three 331 and 14 years prior to anti-IFN-I autoAb onset. However, it is possible that the recorded herpes 332 zoster events might act as a well-documented indicator of other disparate types of severe 333 infections that may also have occurred in these patients, perhaps closer to the time of anti-IFN-I 334 autoAb development. In this regard, it is notable that a previous study postulated that a range of 335 recurrent severe or chronic infections may be factors in promoting the development of autoAbs, 336 including against IFN-Is, in certain infection-susceptible immunodeficient individuals (Walter et 337 al., 2015). To explore this further on a case-by-case basis in our sub-cohort, we looked for

338 additional recorded infection-related clinical events that occurred up to one year prior to first 339 detection of anti-IFN-I autoAbs. One individual (P4) was reported to have recently suffered from 340 a severe pneumonia with sepsis that led to hospitalization. Respiratory samples taken from P4 341 at this time were found to be PCR-positive for influenza A virus and bocavirus, the former agent 342 being paradigmatic for inducing significant IFN-I responses (Dunning et al., 2018). Another 343 individual (P7) was treated for HCV infection with ribavirin and pegylated IFN α , but the normal 344 course of treatment was cut short for an unknown reason, and P7 developed anti-IFNa2 345 autoAbs during this period. Thus, our finding of a small, yet statistically significant, association 346 between prior herpes zoster diagnoses and anti-IFN-I autoAb development, together with 347 additional case-by-case analyses of individual infection-related events, may support the concept 348 that previous infections might influence autoAb induction (Walter et al., 2015). Mechanistically, 349 as discussed below for the IFN α -treated individual (P7), this could be due to events that 350 increase levels of the IFN-I 'immunogen' for subsequent autoAb development, which could 351 include severe infections.

352

353 **Pre-existing autoimmune reactivity predicts subsequent anti-IFN-I autoAb development.**

354 While exposure to virus-induced IFN-I may act as the 'immunogen' for triggering anti-IFN-I 355 autoAb production, a compromised ability to tolerate self-antigens, including IFN-Is, is likely an 356 essential additional requirement for autoAb development. For example, defects in genes relating 357 to correct thymus function, key to self-tolerance mechanisms, have been clearly linked to the 358 early lifetime development of anti-IFN-I autoAbs (Bodansky et al., 2022; Le Voyer et al., 2023; 359 Meager et al., 2006; Ramakrishnan et al., 2018). Furthermore, in the elderly, it may be that 360 common age-related thymic decline plays a key role in reducing self-tolerance and promoting 361 autoAb development in some individuals (Liang et al., 2022). Given the availability of longitudinal 362 clinical data and samples for our sub-cohort, we speculated that further analysis may reveal 363 evidence of general loss of self-tolerance that precedes induction of anti-IFN-I autoAbs in certain

364 patients. We therefore initially searched the available clinical records of patients we had 365 analysed for anti-IFN-I autoAbs to identify instances where their autoimmune status had been 366 assessed by ANA (anti-nuclear antigen) test. While the number of patients tested due to clinical need was small (n=4 for those with anti-IFN-I autoAbs, n=12 for matched controls), there was 367 368 nevertheless a statistically significant association between prior ANA test positivity and 369 subsequent development of anti-IFN-I autoAbs in our sub-cohort (p = 0.02692; Fig. 4C). To test 370 the association between loss of self-tolerance (e.g. ANA positivity) and subsequent anti-IFN-I 371 autoAb induction more formally, we next selected 22 out of our 35 anti-IFN-I autoAb positive 372 patients for whom we had at least 5 years of validated anti-IFN-I autoAb negativity prior to anti-373 IFN-I autoAb development. For each patient, we obtained the two plasma samples taken 374 immediately before the first confirmed detection of anti-IFN-I autoAbs (this was typically 6 375 months and 1 year prior), and used a multiplexed bead-based assay to screen these samples for 376 IgG autoAbs binding to 19 different human autoantigens associated with autoimmune disease, 377 including those likely detected by the clinical ANA test. In parallel, age-matched samples from 22 378 (negative) patients who never developed anti-IFN-I autoAbs were also tested. Using standard 379 deviation thresholds based on these negative patient samples, we identified 11 patients with IgG 380 autoAbs targeting diverse ANA-related and non-related autoantigens, and it was striking that all 381 of these 11 patients (100%) were positive individuals who subsequently went on to develop anti-382 IFN-I autoAbs (Fig. 4D). None of the 22 anti-IFN-I autoAb negative patients exhibited 383 autoreactivity to these other autoantigens. There was no apparent specificity to the observed 384 prior autoreactivity in those who went on to develop anti-IFN-I autoAbs, with different patients 385 harboring IgG targeting distinct autoantigens (including β2-GPI, Ku, Mi-2, PCNA, RNP, RNP/Sm, 386 SSA/Ro60, and SSB/La). However, it is interesting to note that anti-SSA and anti-SSB autoAbs 387 are associated with primary Sjögren's syndrome where frequent development of anti-IFN-I 388 autoAbs has been reported (Burbelo et al., 2019; Gupta et al., 2016). These data amounted to a 389 statistically highly significant association between prior autoimmune autoAb positivity and subsequent development of anti-IFN-I autoAbs (p = 0.0009766; **Fig. 4E**). Overall, the statistically significant association between prior ANA test positivity and subsequent development of anti-IFN-I autoAbs, together with our experimental identification of autoreactivity in 50% of those who went on to produce anti-IFN-I autoAbs, indicate that diminished self-tolerance can precede anti-IFN-I autoAb development. Furthermore, these data suggest that those with certain autoimmune diseases, which might be detectable by routine assays such as ANA screening, are at higher risk of subsequently developing anti-IFN-I autoAbs.

397

398 Development and lifelong persistence of neutralizing anti-IFN α autoAbs potentially 399 triggered by therapeutic IFN α in an individual with pre-existing autoimmunity.

400 Based on previous hypotheses (Hale, 2023), and the data presented so far in this manuscript, 401 we postulate that anti-IFN-I autoAbs develop following exposure to unusually high levels of IFN-I 402 (possibly driven by severe infection) in the context of diminished self-tolerance. Towards 403 validating this concept, we followed-up on the case of individual P7, who developed neutralizing 404 anti-IFN α autoAbs in their mid-50s, and maintained them lifelong ever since (>12 years) (Fig. 405 5A). P7 was initially diagnosed with HCV in their mid-40s, and was treated with the standard of 406 care at the time, ribavirin and pegylated IFN α , eight years later. Treatment with pegylated IFN α 407 was started only 5 weeks before neutralizing anti-IFNa autoAbs were first detected, and all 408 previous samples tested (>12 years) were negative for anti-IFN α autoAbs (Fig. 5A). This 409 observation is highly suggestive that the treatment of P7 with pegylated IFN α may have 410 stimulated the production of long-lasting anti-IFN α autoAbs in a manner similar to that previously 411 reported in a single case (Jorns et al., 2006). However, such occurrences would seem to be the 412 atypical situation, as although production of anti-IFN α autoAbs has been described to occur in 413 response to recombinant IFNa treatment, production appears to be transient and usually self-414 resolving, at least in the small numbers of individuals (20-40) tested previously (Bell et al., 1994; 415 Jorns et al., 2006; Ronnblom et al., 1992). To formally address this on a larger scale, we took

416 advantage of our access to plasma samples taken from 300 individuals in the SHCS (including 417 P7; **Supplementary Table 1**) who had been treated with pegylated IFN α , and assessed whether 418 they had detectable levels of anti-IFN-I IgG autoAbs. Two samples per patient were tested: the 419 first sample available after IFN α treatment began (typically around 6 months); and the last 420 sample available (typically 10-20 years later). Only 3/300 individuals tested around 6 months 421 after starting IFNa treatment were confirmed to possess anti-IFNa IgG autoAbs in their plasmas 422 (P7, P37, and P38), and only the plasma of P7 neutralized the activity of IFNa (Fig. 5B). For 423 P37 and P38, the presence of anti-IFN α autoAbs was transient, as these autoAbs were not 424 readily detected in the last available plasma samples from these patients, or in any other 425 longitudinal samples available (spanning up to 20 years) (Figs. 5B-D). Analysis of the last 426 available plasma samples from our IFNa-treated cohort revealed that only 2/300 individuals 427 possessed anti-IFN α autoAbs in their plasmas at this timepoint, and both neutralized the activity 428 of IFNα (P7 and P36) (Fig. 5B). Notably, longitudinal analysis of biobanked plasma samples 429 from P36 (spanning around 15 years) revealed that his induction of anti-IFNa IgG autoAbs 430 occurred about 10 years after IFNa treatment stopped, suggesting that the IFNa treatment was 431 not the acute trigger for anti-IFNα autoAbs in this individual. We also (re)-tested all available 432 longitudinal plasma samples from 5 negative individuals treated with IFNa in case we had 433 missed important sample timepoints. However, despite some low-level transient anti-IFNa IgG 434 autoAb positive 'blips', all these IFNa-treated individuals remained negative for long-lasting 435 neutralizing anti-IFN α autoAbs (Fig. 5E). Thus, we conclude that development of long-lasting 436 neutralizing anti-IFN α autoAbs in response to IFN α treatment (as observed for P7) is an atypical, 437 rare event.

438

Towards understanding why P7 (but none of the other IFNα-treated individuals) developed a
long-lasting neutralizing anti-IFNα IgG autoAb response during treatment, we obtained the two
plasma samples taken immediately prior to IFNα treatment (typically 6 months and 1 year prior)

442 for seven IFNa-treated individuals in addition to P7. We then used a multiplexed bead-based 443 assay to screen these samples for IgG autoAbs binding to a panel of different autoimmune 444 disease-associated autoantigens as a means to identify those with potential breakdown of self-445 tolerance at these timepoints. Notably, P7 had strong unambiguous evidence for autoimmune 446 reactivity (anti- β 2-GPI IgG autoAbs) in his plasma samples prior to developing anti-IFN α 447 autoAbs, while autoreactivity was generally lacking in samples taken from all other patients who 448 did not develop anti-IFNa autoAbs following IFNa treatment (except N36 who had weak 449 reactivity to SSB/La) (Fig. 5F). Furthermore, longitudinal analysis revealed that P7 possessed 450 anti- β 2-GPI IgG autoAbs at least 3 years prior to receiving IFN α treatment and developing long-451 lasting neutralizing anti-IFN α IgG (Fig. 5G). Taken together with our previous observation of a 452 statistically significant association between prior autoreactivity positivity and subsequent anti-453 IFN-I autoAb development, the results of this case-study suggest that a pre-existing breakdown 454 of self-tolerance in P7 was likely to have been decisive in him mounting a long-lasting anti-IFNα 455 IgG response when treated with pegylated IFNa.

- 456
- 457

DISCUSSION

458

459 Herein, we systematically investigated the age- and IFN-I-treatment -related development, long-460 term dynamics, and longevity of anti-IFN-I autoAbs in well-treated individuals enrolled over 461 several decades in the Swiss HIV Cohort Study (SHCS). The unique aspect of our work is the 462 longitudinal analysis of historic biobanked patient samples and clinical records that span the 463 decades before and after each patient developed anti-IFN-I autoAbs. Together with retrospective 464 serological and cellular immunoassays, this allowed us to dissect factors associated with anti-465 IFN-I autoAb induction and their consequences. Our observation that around 1.9% of individuals 466 developed anti-IFN-I autoAbs (1.17% for neutralizing autoAbs only), with a median onset age of 467 ~63 years (range 45-80), aligns exceedingly well with findings from a recent cross-sectional

468 study that noted a sharp increase in neutralizing anti-IFN-I autoAb prevalence (to 1.4%) in 469 otherwise healthy individuals over the age of 70 years, as compared with younger individuals 470 (Bastard et al., 2021). This suggests that the underlying HIV-positive status of individuals within 471 the sub-cohort we studied, the majority of whom were well-treated with long-term antiretroviral 472 therapy, likely has only a limited impact (if any) on anti-IFN-I autoAb development. Our results 473 should therefore also be broadly applicable to the otherwise healthy general aging population, 474 and our data now provide a new high-resolution long-term perspective on this form of IFN 475 system deficiency and its contribution to severe viral disease.

476

477 The induction of anti-IFN-I autoAbs in some individuals around ages 60-65 is enigmatic. Such 478 late-onset development is suggestive that, at least in this population, germline host genetic 479 variants compromising thymic function may play only a limited contribution as compared with the 480 situation in other younger patient populations described to harbor mutations in AIRE or 481 alternative NF-kB pathway genes (Le Voyer et al., 2023; Meager et al., 2006). Nevertheless, our 482 finding that there is a significant temporal association between prior autoimmune reactivity (e.g. 483 via a positive clinical ANA test) and the subsequent development of anti-IFN-I autoAbs is still 484 indicative that these patients may indeed have lost their full self-tolerance capacity. While we 485 cannot rule out an impact of the HIV-1 infection on patient autoimmune status (Roszkiewicz and 486 Smolewska, 2016; Zandman-Goddard and Shoenfeld, 2002), we note that the observed anti-487 IFN-I autoAb prevalence in our sub-cohort is very similar to that in otherwise healthy individuals 488 (Bastard et al., 2021). Given the genetic link between central T-cell tolerance in the thymus and 489 anti-IFN-I autoAb development (Le Voyer et al., 2023; Meager et al., 2006), the most likely 490 explanation in our aged patients is therefore that the natural process of thymic involution has led 491 to reduced thymus activity and thus an overall increased likelihood of general development of 492 autoimmunity (Liang et al., 2022), including against IFN-Is. Further studies will have to address 493 this hypothesis directly, as well as understand why only a subset of aged individuals go on to

494 develop such autoimmune reactions. In this regard, the availability of longitudinal biobanked 495 plasma and PBMC samples, together with high-resolution tracking of anti-IFN-I autoAb induction 496 (such as presented here), could prove invaluable to retrospectively assess thymus-related 497 immunosenescence in specific aging individuals by assaying historic thymic output (e.g. by 498 guantifying T-cell receptor excision circles, TRECs; (Mitchell et al., 2010)) and correlating this 499 directly with the subsequent likelihood of anti-IFN-I autoAb induction. Given the apparent severe 500 consequences of anti-IFN-I autoAbs for infection susceptibility (reviewed in (Bastard et al., 501 2024a; Hale, 2023)), in the future there may be a clear clinical role for performing diagnostic 502 autoimmune (e.g. ANA test and others) or TREC quantifications to help predict an individual's 503 risk of developing this form of IFN system deficiency.

504

505 While aging and prior autoimmune reactivity appear to pre-dispose an individual to develop anti-506 IFN-I autoAbs, the 'two-hit' hypothesis suggests that (auto)immunization with IFN-I is a 507 subsequently required trigger in this process (Hale, 2023). Our finding of a statistical association 508 (albeit weak) between prior recorded virus infections such as reactivated herpes zoster, which 509 activates a clear endogenous IFN-I response in patients (Vandoren et al., 2024), and 510 development of anti-IFN-I autoAbs provides some support to the idea that autoimmunization 511 may occur. Similar support comes from our anecdotal finding that anti-IFN-I autoAbs developed 512 in a patient immediately following hospitalization with severe pneumonia possibly caused by 513 influenza A virus, again a scenario where endogenous IFN-I and inflammatory responses will be 514 activated (Dunning et al., 2018). We also cannot rule out that a subset of our patients had 515 specific sub-clinical undiagnosed systemic autoimmune diseases, such as primary Sjögren's 516 syndrome or systemic lupus erythematosus, which provided an environment where both loss of 517 tolerance and atypically increased levels of IFN-I triggered anti-IFN-I autoAb development 518 (Burbelo et al., 2019; Gupta et al., 2016; Mathian et al., 2022; Trutschel et al., 2022). However, 519 additional evidence supporting the 'two-hit' hypothesis comes from our analysis of 300

520 individuals who were treated (or 'immunized') with pegylated IFNa, where we identified that a 521 single individual with unambiguous evidence for loss of self-tolerance prior to therapy was the 522 only individual to generate long-lasting neutralizing anti-IFNa IgG in response to the exogenous 523 IFNa. Overall, this could suggest that some previous acute infections in tolerance-compromised 524 individuals might lead to development of anti-IFN-I autoAbs, and could thus have long-term 525 consequences for enhancing susceptibility to future severe infections. This concept may also 526 apply to some individuals who are still treated therapeutically with IFN-Is (EASL, 2023), and 527 given the 'two-hit' hypothesis it may be worth considering future implementation of diagnostic 528 autoimmune pre-screening and risk-benefit evaluations to assess the likely short- and long- term 529 outcomes associated with IFN-I treatment specifically in those with poor self-tolerance.

530

531 In contrast to previous cross-sectional studies (Abers et al., 2021; Bastard et al., 2020; Kisand et 532 al., 2008; Koning et al., 2021; Lopez et al., 2021; van der Wijst et al., 2021; Wang et al., 2021), 533 our access to high-resolution longitudinal samples gave us the unique opportunity to study the 534 within-individual consequences of neutralizing anti-IFN-I autoAb development. Compared to 535 samples taken from before anti-IFN-I autoAbs were detectable, we observed a clear temporal 536 correlation between induction of neutralizing anti-IFNa2 autoAbs and a reduction of baseline ISG 537 levels in patient PBMCs. It is logical to assume that the appearance and maintenance of these 538 neutralizing autoAbs led to this functional impairment of innate antiviral immunity, thus 539 contributing to an increased susceptibility to severe viral infections as previously reported 540 (reviewed in (Bastard et al., 2024a; Hale, 2023)). The consequences of harboring other 541 neutralizing anti-IFN-I autoAbs (e.g. against IFN β or IFN ω) could not be readily discerned in our 542 sub-cohort due to the relatively low numbers of positive individuals identified, although a recent 543 report suggests that neutralization of IFN α may have greater pathogenic consequences than 544 neutralization of IFN ω (Bastard et al., 2024b). Nevertheless, a key finding from our work was the 545 observation that following induction, neutralizing anti-IFN-I autoAbs can be effectively

546 maintained in the circulation lifelong (over at least 15 years in one individual), meaning that the 547 consequences of anti-IFN-I development could result in extremely long-lasting IFN-I functional 548 deficiency and increased susceptibility to infection. Transient induction of anti-IFN-I autoAbs has 549 been described in some infection scenarios (Chang et al., 2021; Steels et al., 2022), as well as 550 in this study, and could potentially have important physiological regulatory functions such as 551 dampening immunopathologies (Babcock et al., 2024). However, a distinction should be made 552 with the class of long-lasting, lifelong neutralizing anti-IFN-I autoAbs that we mainly describe 553 here, and which functionally impair innate antiviral immunity.

554

555 Our study has some limitations, including the retrospective nature and potential biases inherent 556 in long-term cohort studies. For example, as the SHCS was not specifically established to study 557 clinical aspects of autoAbs, autoimmune results (e.g. ANA tests) were only available for some 558 patients that were performed based on clinical need. However, we were able to address this 559 specific deficiency through systematic measurements made retrospectively from biobanked 560 samples. Furthermore, not all (viral) infections can be recorded in an observational cohort study, 561 and the low prevalence of neutralizing anti-IFN-I autoAbs limits the power to assess their impact 562 on subsequent infections. While we believe that the results from our work should also be broadly 563 applicable to otherwise healthy general populations, we also acknowledge that all of our study 564 patients are people living with HIV, and we thus cannot rule out potential confounding factors 565 related to the infection, unknown opportunistic co-infections, or the effects of antiretroviral 566 therapy that could limit the generalizability of our study. In this regard, a major limitation to 567 studying the functional consequences of anti-IFN-I autoAbs was actually that we could not 568 effectively assess their impact on HIV-1 replication due to the majority of patients being on long-569 term antiretroviral therapy and therefore exhibiting virological suppression at the time of anti-IFN-570 I autoAb detection. Our initial sampling strategy (>65 years of age) may also have biased our 571 assessment of anti-IFN-I autoAb lifelong persistence, and we may not yet have a true

appreciation of transient anti-IFN-I autoAb induction. While future investigations with larger and more diverse cohorts are therefore clearly essential, we also highlight the unique resource that the SHCS represents for studies such as this given the rarity of decade-spanning longitudinallysampled aging cohorts focused on infectious diseases with the numbers of patients required to reveal uncommon anti-IFN-I autoAbs.

577

578 In summary, our study provides a comprehensive longitudinal exploration of the age-related 579 development and specificities of anti-IFN-I autoAbs. Our work identifies prior infection and 580 autoimmune factors that influence the likelihood of anti-IFN-I autoAb induction, and thereby 581 supports the hypothesis that at least 'two-hits' probably underlie this process. These findings 582 have implications for diagnosing, perhaps through routine screening of 'at-risk' individuals with 583 known autoimmune conditions, those who may be pre-disposed to develop anti-IFN-I autoAbs 584 and the lifelong IFN-I functional deficiency that results. Broader knowledge in this area should 585 contribute to the development of targeted strategies to mitigate severe viral disease 586 susceptibility.

- 587
- 588

MATERIALS AND METHODS

589

590 **Patient samples, data and ethics.** The 1876 plasma samples from patients >65 years at the 591 time of initial testing (Supplementary Table 1), 300 plasma samples from patients treated with 592 pegylated IFNα (Supplementary Table 1), and all retrospective follow-up longitudinal samples 593 (including plasma and/or PBMCs) analyzed in this study were derived from samples stored in 594 the biobanks of the Swiss HIV Cohort study (SHCS). The SHCS is a prospective, nationwide, 595 longitudinal, noninterventional, observational, clinic-based cohort with semiannual visits and 596 blood collections, enrolling all PLH in Switzerland since 1988 (Scherrer et al., 2022). The SHCS 597 maintains comprehensive, longitudinal, anonymous data collections for all participants, including

598 extensive clinical and demographic data. The data are collected by the five Swiss university 599 hospitals, two cantonal hospitals, 15 affiliated hospitals and 36 private physicians (listed 600 in http://www.shcs.ch/180-health-care-providers). Detailed information on the study is available 601 at http://www.shcs.ch. The SHCS has been approved by the ethics committees of all 602 participating institutions (Kantonale Ethikkommission Bern, Ethikkommission des Kantons St. 603 Gallen, Comite Departemental d'Ethique des Specialites Medicales et de Medicine 604 Communataire et de Premier Recours, Kantonale Ethikkommission Zürich, Repubblica et 605 Cantone Ticino-Comitato Ethico Cantonale, Commission Cantonale d'Étique de la Recherche 606 sur l'Être Humain, Ethikkommission beider Basel), and written informed consent has been 607 obtained from all participants. The personnel who conducted the work with patient samples had 608 no information on patient demographics at the time of analysis, and all data have subsequently 609 been analyzed anonymously.

610 Analysis of Autoreactive IgG in Plasma Samples. A previously described high-throughput 611 multiplexed bead-based assay was implemented to assay patient plasma samples for anti-IFN-I 612 IgG (Achleitner et al., 2024; Busnadiego et al., 2022; Liechti et al., 2018). Briefly, magnetic 613 beads (MagPlex-C Microspheres, Luminex) were coupled to recombinant carrier-free human 614 IFN-Is (IFNα2, Novus Biologicals; IFNβ, PeproTech; or IFNω, Novus Biologicals) at a 615 concentration of 10µg protein per million beads, or left empty. Bead coating efficiency and bead 616 specificity were assessed using mouse monoclonal antibodies as described previously 617 (Busnadiego et al., 2022). For serological testing, obtained patient plasma samples were heat-618 inactivated at 56°C for 1h before being diluted 1:50 in PBS supplemented with 1% BSA 619 (PBS/BSA) and incubated in 96-well plates with 1:1:1:1 mixtures of IFNα2:IFNβ:IFNω:empty beads (2x10³ beads per region per well; 1:100 final concentration of plasma). On all 620 621 experimental plates, a human polyclonal anti-IFN α 2b antiserum (BEI resources) was used as a 622 positive control, and an in-house healthy donor pool of human plasmas was used both as a 623 negative control and for batch normalization. Following incubation of the bead:plasma mixes for

624 1h at room temperature, beads were washed twice with PBS/BSA before phycoerythrin (PE)-625 labeled secondary antibodies were added separately in PBS/BSA (pan-IgG, 1:500 dilution, 626 Southern Biotech; IgG1, 1:500 dilution, Southern Biotech; IgG2, 1:100 dilution, Southern 627 Biotech; IgG3, 1:100 dilution, Southern Biotech; IgG4, 1:100 dilution, Southern Biotech). After a 628 further 1h incubation at room temperature, bead mixtures were washed twice in PBS/BSA and 629 samples were analyzed on a FlexMap 3D instrument (Luminex). A minimum of 50 beads per 630 antigen were acquired. For each plasma sample, Median Fluorescence Intensity (MFI) values 631 from the IFN-I-coated beads were obtained and made relative to the corresponding MFI value 632 obtained from the empty beads (fold over empty, FOE). Values were then normalized between 633 plates and cohorts using results from the in-house healthy donor pool. In initial screenings, 634 patient plasmas exhibiting normalized FOE values >2 MFI were considered positive for the 635 specific anti-IFN-I IgG. Available longitudinal plasma samples were then obtained for re-testing 636 of all positive patients and selected negative patients. When assaying longitudinal samples, 637 patient plasmas exhibiting normalized FOE values >10 standard deviations (SDs) above the 638 mean MFIs of the first 5 available samples from each individual patient were considered positive 639 for the specific anti-IFN-I IgG.

640

641 To assay patient plasma samples for IgG targeting various human autoantigens associated with 642 autoimmune diseases, a customized 19 autoantigen-containing MILLIPLEX® Human 643 Autoimmune Autoantibody Panel (Merck Millipore) was used. The assay was performed 644 according to the manufacturer's protocol using a 1:300 final dilution of each heat-inactivated 645 patient plasma, and samples were analyzed on a FlexMap 3D instrument (Luminex). For each 646 plasma sample, FOE MFI values for IgG targeting each autoantigen were calculated as 647 described above. Within the dataset for each autoantigen, FOE values were then normalized to 648 the mean MFI values obtained from the anti-IFN-I autoAb-negative patient samples. Patient 649 plasmas exhibiting normalized FOE values >5 SDs above the mean MFIs obtained from the anti-

IFN-I autoAb-negative patient samples were considered positive for the specific anti-autoantigenIgG.

652

653 Analysis of IFN-I Neutralization in Plasma Samples. IFN-I neutralization was assessed as 654 described previously using a 293T transient-transfection based dual-luciferase reporter assay in 655 96-well plates that is based around co-transfection of a plasmid containing the firefly luciferase 656 (FF-Luc) gene under control of the IFN-inducible mouse Mx1 promoter (pGL3-Mx1P-FFluc) 657 (kindly provided by Georg Kochs) with a plasmid constitutively expressing the Renilla luciferase 658 (Ren-Luc) gene (pRL-TK-Renilla) (Busnadiego et al., 2022). Twenty-four hours post-transfection 659 of both plasmids, heat-inactivated patient plasma samples (or multiple negative controls) were 660 diluted 1:50 in DMEM supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin and 661 100 mg/mL streptomycin, and incubated for 1h at room temperature with 10, 1 or 0.2 ng/mL of 662 IFN α 2 or IFN ω , or with 1, 0.2 or 0.04 ng/mL of IFN β , prior to their addition to the transfected 663 cells. After 24h, cells were lysed for 15 min at room temperature and FF-Luc and Ren-Luc 664 activity levels were determined using the Dual-Luciferase Reporter Assay System (Promega) 665 and a PerkinElmer EnVision plate reader (EV2104) according to the manufacturers' instructions. 666 FF-Luc values were normalized to Ren-Luc values and then to the median luminescence 667 intensity of control wells that had not been stimulated with any IFN-I. Patient plasmas that 668 reduced IFN-I-stimulated FF-Luc/Ren-Luc values by >2 SDs below the mean values of the 669 negative control samples were considered to be neutralizing.

670

Analysis of ISG Expression in PBMC Samples. Thirteen patients who developed persistent neutralizing anti-IFNα autoAbs (positive patients) were selected, together with 13 age-matched control patients who were confirmed longitudinally to have never developed anti-IFN-I autoAbs (negative patients). For each positive patient, we obtained biobanked frozen PBMC samples corresponding to 2-3 annual donations given before development of anti-IFNα autoAbs and 2-3

676 annual donations given after development of autoAbs. For each negative patient, we obtained 677 similar biobanked frozen PBMC samples corresponding to equivalent timepoints. Total RNA 678 from freshly thawed PBMCs was extracted using the ReliaPrep[™] RNA Cell Miniprep System 679 (Promega), and mRNA was subsequently reverse transcribed into cDNA with an oligo(dT) 680 primer using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific) according to the 681 manufacturer's instructions. Real-time PCR was then performed with PowerTrack[™] SYBR 682 Green Master Mix (Thermo Fisher Scientific) using gene-specific forward and reverse primers 683 (sequences available upon request) in a 7300 Real-Time PCR System (Applied Biosystems). 684 Relative gene expression was calculated with the $\Delta\Delta$ Ct method. Data were normalized to 685 GAPDH levels, averaged between the 2-3 annual donations per patient and per timepoint, and 686 were expressed as percent change relative to the first timepoint (i.e. before development of anti-687 IFNa autoAbs for the positive patients, or to the equivalent timepoint for the age-matched 688 negative patients). Statistical significance was determined based on the Δ Ct values (normalized 689 to GAPDH) using a Mann-Whitney U test.

690

691 Statistical Analyses. Patient clinical and demographic data derived from the SHCS relating to 692 the content of Supplementary Tables 1-3, blood cell compositions, prior CMV positivity, prior 693 herpes zoster diagnoses, and prior ANA test positivity were examined using the Wilcoxon rank-694 sum test (for continuous variables), or Fisher's exact test (for categorical variables). In addition, 695 conditional logistic regression models were performed to take into account the effect of matching 696 cases and controls. Analyses were performed using R version 4.2.2., with statistical tests noted 697 in the appropriate figure legends. All other statistical analyses presented were performed in 698 GraphPad Prism 9 using the statistical tests noted in the appropriate figure legends.

699

700

ACKNOWLEDGMENTS

701

702 We thank the patients participating in the SHCS and their physicians and study nurses for 703 patient care. The members of the SHCS are Abela IA, Aebi-Popp K, Anagnostopoulos A, 704 Battegay M, Bernasconi E, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier 705 G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H, Fux CA, Günthard HF (President of the SHCS), 706 Hachfeld A, Haerry D (Deputy of 'Positive Council'), Hasse B, Hirsch HH, Hoffmann M, Hösli I, 707 Huber M, Jackson-Perry D (patient representative), Kahlert CR (Chairman of the Mother & Child 708 Substudy), Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Kuseiko K (Head of Data 709 Centre), Labhardt N, Leuzinger K, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, 710 Nemeth J, Nicca D, Notter J, Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the 711 Scientific Board), Salazar-Vizcaya L, Schmid P, Speck R, Stöckle M (Chairman of the Clinical 712 and Laboratory Committee), Tarr P, Trkola A, Wandeler G, Weisser M, and Yerly S. We are 713 grateful to Nadine Rist, Stefan Schmutz, and Kevin Steiner (University of Zurich, Switzerland) for 714 technical support and sample management. We are also grateful to Alexandra Calmy (University 715 of Geneva, Switzerland) and to Matthias Cavassini (University of Lausanne, Switzerland) for 716 their support as representatives of SHCS centers. Financial support for this study was provided 717 by the Swiss National Science Foundation (SNF; grants 31003A 182464 and 310030 214957 718 to BGH), the Novartis Foundation for Medical-Biological Research (grant 23A069 to BGH), and 719 the Promedica Foundation (to IAA). The study was also co-financed within the framework of the 720 Swiss HIV Cohort Study (SHCS), supported by the SNF (33CS30_201369 to HFG), by the small 721 nested SHCS project 898 (to BGH and IAA). The funders had no role in study design, data 722 collection and analysis, decision to publish, or preparation of the manuscript. The authors 723 declare no competing financial interests.

724

725

CONFLICT OF INTEREST STATEMENT

726

727 IAA received the Swiss Fellowship Gilead research grant and participated in advisory boards 728 from Astra Zeneca and Moderna. EB received travel grants and payments for participation in 729 advisory boards from Gilead Sciences, MSD, ViiV Healthcare, Pfizer, Abbvie, Astra Zeneca, 730 Moderna and Ely Lilly. AR received support for advisory boards and/or travel grants from MSD, 731 Gilead Sciences, Pfizer and Moderna. HFG received unrestricted research grants from Gilead 732 Sciences; fees for data and safety monitoring board membership from Merck; 733 consulting/advisory board membership fees from Gilead Sciences, Merck, Johnson and 734 Johnson, Janssen, GSK, Novartis and ViiV Healthcare; and grants from the Swiss National 735 Science Foundation, the Bill and Melinda Gates Foundation, the Yvonne Jacob Foundation, 736 Gilead Sciences, ViiV Healthcare and the National Institutes of Health. All the reported grants 737 and remuneration were provided outside the context of this work. All other authors did not report 738 any disclosures.

739

REFERENCES

- 740
- Abers, M.S., L.B. Rosen, O.M. Delmonte, E. Shaw, P. Bastard, L. Imberti, V. Quaresima, A. Biondi, P.
 Bonfanti, R. Castagnoli, J.L. Casanova, H.C. Su, L.D. Notarangelo, S.M. Holland, and M.S.
 Lionakis. 2021. Neutralizing type-I interferon autoantibodies are associated with delayed viral
 clearance and intensive care unit admission in patients with COVID-19. *Immunology and cell biology* 99:917-921.
- Achleitner, M., N.K. Mair, J. Danhardt, R. Kardashi, M.A. Puhan, I.A. Abela, N. Toepfner, K. de With, W.
 Kanczkowski, N. Jarzebska, R.N. Rodionov, C. Wolf, M.A. Lee-Kirsch, C. Steenblock, B.G. Hale,
 and S.R. Bornstein. 2024. Absence of Type I Interferon Autoantibodies or Significant Interferon
 Signature Alterations in Adults With Post-COVID-19 Syndrome. *Open Forum Infect Dis* 11:ofad641.
- Akbil, B., T. Meyer, P. Stubbemann, C. Thibeault, O. Staudacher, D. Niemeyer, J. Jansen, B. Muhlemann,
 J. Doehn, C. Tabeling, C. Nusshag, C. Hirzel, D.S. Sanchez, A. Nieters, A. Lother, D. Duerschmied,
 N. Schallner, J.N. Lieberum, D. August, S. Rieg, V. Falcone, H. Hengel, U. Kolsch, N. Unterwalder,
 R.H. Hubner, T.C. Jones, N. Suttorp, C. Drosten, K. Warnatz, T. Spinetti, J.C. Schefold, T. Dorner,
 L.E. Sander, V.M. Corman, U. Merle, C.s.G. Pa, F. Kurth, H. von Bernuth, C. Meisel, and C.
 Goffinet. 2022. Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I
 Interferon Auto-antibodies. *Journal of clinical immunology* 42:1111-1129.
- Alotaibi, F., N.K. Alharbi, L.B. Rosen, A.Y. Asiri, A.M. Assiri, H.H. Balkhy, M. Al Jeraisy, Y. Mandourah, S.
 AlJohani, S. Al Harbi, H.A.A. Jokhdar, A.M. Deeb, Z.A. Memish, J. Jose, S. Ghazal, S. Al Faraj,
 G.A. Al Mekhlafi, N.M. Sherbeeni, F.E. Elzein, B.M. AlMutairi, A. Al-Dawood, M.L. Abdullah, T.
 Barhoumi, M.W. Alenazi, A. Almasood, S.M. Holland, Y.M. Arabi, and G. Saudi Critical Care Trials.

- Type I interferon autoantibodies in hospitalized patients with Middle East respiratory
 syndrome and association with outcomes and treatment effect of interferon beta-1b in MIRACLE
 clinical trial. *Influenza Other Respir Viruses* 17:e13116.
- Babcock, B.R., A. Kosters, D.J. Eddins, M.S.B. Donaire, S. Sarvadhavabhatla, V. Pae, F. Beltran, V.W.
 Murray, G. Gill, G. Xie, B.S. Dobosh, V.D. Giacalone, R.M. Tirouvanziam, R.P. Ramonell, S.A.
 Jenks, I. Sanz, F.E.-H. Lee, N.R. Roan, S.A. Lee, and E.E.B. Ghosn. 2024. Transient anti-interferon autoantibodies in the airways are associated with efficient recovery from COVID-19. *medRxiv* 2024.2001.2011.24301000.
- Bastard, P., A. Gervais, T. Le Voyer, Q. Philippot, A. Cobat, J. Rosain, E. Jouanguy, L. Abel, S.Y. Zhang,
 Q. Zhang, A. Puel, and J.L. Casanova. 2024a. Human autoantibodies neutralizing type I IFNs: From
 1981 to 2023. *Immunol Rev*
- 772 Bastard, P., A. Gervais, T. Le Voyer, J. Rosain, Q. Philippot, J. Manry, E. Michailidis, H.H. Hoffmann, S. 773 Eto, M. Garcia-Prat, L. Bizien, A. Parra-Martinez, R. Yang, L. Haljasmagi, M. Migaud, K. 774 Sarekannu, J. Maslovskaja, N. de Prost, Y. Tandjaoui-Lambiotte, C.E. Luyt, B. Amador-Borrero, A. 775 Gaudet, J. Poissy, P. Morel, P. Richard, F. Cognasse, J. Troya, S. Trouillet-Assant, A. Belot, K. 776 Saker, P. Garcon, J.G. Riviere, J.C. Lagier, S. Gentile, L.B. Rosen, E. Shaw, T. Morio, J. Tanaka, 777 D. Dalmau, P.L. Tharaux, D. Sene, A. Stepanian, B. Megarbane, V. Triantafyllia, A. Fekkar, J.R. 778 Heath, J.L. Franco, J.M. Anaya, J. Sole-Violan, L. Imberti, A. Biondi, P. Bonfanti, R. Castagnoli, 779 O.M. Delmonte, Y. Zhang, A.L. Snow, S.M. Holland, C. Biggs, M. Moncada-Velez, A.A. Arias, L. 780 Lorenzo, S. Boucherit, B. Coulibaly, D. Anglicheau, A.M. Planas, F. Haerynck, S. Duvlis, R.L. 781 Nussbaum, T. Ozcelik, S. Keles, A.A. Bousfiha, J. El Bakkouri, C. Ramirez-Santana, S. Paul, Q. 782 Pan-Hammarstrom, L. Hammarstrom, A. Dupont, A. Kurolap, C.N. Metz, A. Aiuti, G. Casari, V. 783 Lampasona, F. Ciceri, L.A. Barreiros, E. Dominguez-Garrido, M. Vidigal, M. Zatz, D. van de Beek, 784 S. Sahanic, I. Tancevski, Y. Stepanovskyy, O. Boyarchuk, Y. Nukui, M. Tsumura, L. Vidaur, S.G. 785 Tangye, S. Burrel, D. Duffy, L. Quintana-Murci, A. Klocperk, N.Y. Kann, A. Shcherbina, Y.L. Lau, D. 786 Leung, M. Coulongeat, J. Marlet, R. Koning, L.F. Reyes, A. Chauvineau-Grenier, F. Venet, G. 787 Monneret, M.C. Nussenzweig, R. Arrestier, I. Boudhabhay, H. Baris-Feldman, D. Hagin, J. Wauters, 788 I. Meyts, A.H. Dyer, S.P. Kennelly, N.M. Bourke, R. Halwani, N.S. Sharif-Askari, K. Dorgham, J. 789 Sallette, S.M. Sedkaoui, S. AlKhater, R. Rigo-Bonnin, F. Morandeira, L. Roussel, D.C. Vinh, S.R. 790 Ostrowski, A. Condino-Neto, C. Prando, A. Bonradenko, A.N. Spaan, L. Gilardin, J. Fellay, S. 791 Lyonnet, K. Bilguvar, R.P. Lifton, S. Mane, H. Lab, C. Clinicians, C.-S. Clinicians, N.I.R.t.C. Group, 792 N.-C.S. Group, C. Danish, S. Danish Blood Donor, H. St. James's, S.C.I. group, C.C.S.G. French, 793 C.-G. Imagine, C. Milieu Interieur, V.C.C. Co, U.M.C.C. Amsterdam, I. Biobank, C.H.G. Effort, C. 794 cohort, C.D. Study, H.-C. Cerba, g. Etablissement du Sang study, M.S. Anderson, B. Boisson, V. 795 Beziat, S.Y. Zhang, E. Vandreakos, O. Hermine, A. Pujol, P. Peterson, T.H. Mogensen, L. Rowen, 796 J. Mond, S. Debette, X. de Lamballerie, X. Duval, F. Mentre, M. Zins, P. Soler-Palacin, R. Colobran, 797 G. Gorochov, X. Solanich, S. Susen, J. Martinez-Picado, D. Raoult, M. Vasse, P.K. Gregersen, L. 798 Piemonti, C. Rodriguez-Gallego, L.D. Notarangelo, H.C. Su, K. Kisand, S. Okada, A. Puel, E. 799 Jouanguy, C.M. Rice, P. Tiberghien, Q. Zhang, A. Cobat, L. Abel, and J.L. Casanova. 2021. 800 Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years 801 old and account for ~20% of COVID-19 deaths. Science immunology 6:
- 802 Bastard, P., A. Gervais, M. Taniguchi, L. Saare, K. Sarekannu, T. Le Voyer, Q. Philippot, J. Rosain, L. 803 Bizien, T. Asano, M. Garcia-Prat, A. Parra-Martinez, M. Migaud, M. Tsumura, F. Conti, A. Belot, 804 J.G. Riviere, T. Morio, J. Tanaka, E. Javouhey, F. Haerynck, S. Duvlis, T. Ozcelik, S. Keles, Y. 805 Tandjaoui-Lambiotte, S. Escoda, M. Husain, Q. Pan-Hammarstrom, L. Hammarstrom, G. Ahlijah, A. 806 Abi Haidar, C. Soudee, V. Arseguel, H. Abolhassani, S. Sahanic, I. Tancevski, Y. Nukui, S. 807 Hayakawa, G.P. Chrousos, A. Michos, E.B. Tatsi, F. Filippatos, A. Rodriguez-Palmero, J. Troya, I. 808 Tipu, I. Meyts, L. Roussel, S.R. Ostrowski, L. Schidlowski, C. Prando, A. Condino-Neto, N. Cheikh, A.A. Bousfiha, J. El Bakkouri, C. Clinicians, G.-C.S. Group, C.H.G. Effort, P. Peterson, A. Pujol, R. 809 810 Levy, P. Quartier, D.C. Vinh, B. Boisson, V. Beziat, S.Y. Zhang, A. Borghesi, A. Pession, E. 811 Andreakos, N. Marr, A.A. Mentis, T.H. Mogensen, C. Rodriguez-Gallego, P. Soler-Palacin, R. 812 Colobran, V. Tillmann, B. Neven, S. Trouillet-Assant, P. Brodin, L. Abel, E. Jouanguy, Q. Zhang, F. 813 Martinon-Torres, A. Salas, A. Gomez-Carballa, L.I. Gonzalez-Granado, K. Kisand, S. Okada, A. 814 Puel, A. Cobat, and J.L. Casanova. 2024b. Higher COVID-19 pneumonia risk associated with anti-815 IFN-alpha than with anti-IFN-omega auto-Abs in children. The Journal of experimental medicine 816 221:

- 817 Bastard, P., L.B. Rosen, Q. Zhang, E. Michailidis, H.H. Hoffmann, Y. Zhang, K. Dorgham, Q. Philippot, J. 818 Rosain, V. Beziat, J. Manry, E. Shaw, L. Haljasmagi, P. Peterson, L. Lorenzo, L. Bizien, S. Trouillet-819 Assant, K. Dobbs, A.A. de Jesus, A. Belot, A. Kallaste, E. Catherinot, Y. Tandjaoui-Lambiotte, J. Le 820 Pen, G. Kerner, B. Bigio, Y. Seeleuthner, R. Yang, A. Bolze, A.N. Spaan, O.M. Delmonte, M.S. 821 Abers, A. Aiuti, G. Casari, V. Lampasona, L. Piemonti, F. Ciceri, K. Bilguvar, R.P. Lifton, M. Vasse, 822 D.M. Smadja, M. Migaud, J. Hadjadj, B. Terrier, D. Duffy, L. Quintana-Murci, D. van de Beek, L. 823 Roussel, D.C. Vinh, S.G. Tangye, F. Haerynck, D. Dalmau, J. Martinez-Picado, P. Brodin, M.C. 824 Nussenzweig, S. Boisson-Dupuis, C. Rodriguez-Gallego, G. Vogt, T.H. Mogensen, A.J. Oler, J. Gu, 825 P.D. Burbelo, J.I. Cohen, A. Biondi, L.R. Bettini, M. D'Angio, P. Bonfanti, P. Rossignol, J. Mayaux, 826 F. Rieux-Laucat, E.S. Husebye, F. Fusco, M.V. Ursini, L. Imberti, A. Sottini, S. Paghera, E. Quiros-827 Roldan, C. Rossi, R. Castagnoli, D. Montagna, A. Licari, G.L. Marseglia, X. Duval, J. Ghosn, H. 828 Lab, N.-U.I.R.t.C. Group, C. Clinicians, C.-S. Clinicians, C.G. Imagine, C.C.S.G. French, C. Milieu 829 Interieur, V.C.C. Co, U.M.C.C.-B. Amsterdam, C.H.G. Effort, J.S. Tsang, R. Goldbach-Mansky, K. 830 Kisand, M.S. Lionakis, A. Puel, S.Y. Zhang, S.M. Holland, G. Gorochov, E. Jouanguy, C.M. Rice, A. 831 Cobat, L.D. Notarangelo, L. Abel, H.C. Su, and J.L. Casanova. 2020. Autoantibodies against type I 832 IFNs in patients with life-threatening COVID-19. Science 370:
- Baumann, L., D.L. Braun, M. Cavassini, M. Stoeckle, E. Bernasconi, P. Schmid, A. Calmy, D. Haerry, C.
 Beguelin, C.A. Fux, G. Wandeler, B. Surial, and A. Rauch. 2024. Long-term trends in hepatitis C
 prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study. *Liver Int*44:169-179.
- Bayat, A., P.D. Burbelo, S.K. Browne, M. Quinlivan, B. Martinez, S.M. Holland, A. Buvanendran, J.S.
 Kroin, A.J. Mannes, J. Breuer, J.I. Cohen, and M.J. Iadarola. 2015. Anti-cytokine autoantibodies in postherpetic neuralgia. *J Transl Med* 13:333.
- 840 Bell, J.B., R. Barfoot, T. Iveson, R.L. Powles, and B.C. Millar. 1994. Neutralising antibodies in patients with 841 multiple myeloma receiving maintenance therapy with interferon alpha 2b. *Br J Cancer* 70:646-651.
- 842 Bodansky, A., S.E. Vazquez, J. Chou, T. Novak, A. Al-Musa, C. Young, M. Newhams, S. Kucukak, L.D. 843 Zambrano, A. Mitchell, C.Y. Wang, K. Moffitt, N.B. Halasa, L.L. Loftis, S.P. Schwartz, T.C. Walker, 844 E.H. Mack, J.C. Fitzgerald, S.J. Gertz, C.M. Rowan, K. Irby, R.C. Sanders, Jr., M. Kong, J.E. 845 Schuster, M.A. Staat, M.S. Zinter, N.Z. Cvijanovich, K.M. Tarquinio, B.M. Coates, H.R. Flori, M.K. 846 Dahmer, H. Crandall, M.L. Cullimore, E.R. Levy, B. Chatani, R. Nofziger, C.-N.S.G.I. Overcoming, 847 R.S. Geha, J. DeRisi, A.P. Campbell, M. Anderson, and A.G. Randolph. 2022. NFKB2 848 haploinsufficiency identified via screening for IFNalpha2 autoantibodies in children and adolescents 849 hospitalized with SARS-CoV-2-related complications. J Allergy Clin Immunol
- Burbelo, P.D., S. Browne, S.M. Holland, M.J. Iadarola, and I. Alevizos. 2019. Clinical features of Sjogren's syndrome patients with autoantibodies against interferons. *Clin Transl Med* 8:1.
- Burbelo, P.D., S.K. Browne, E.P. Sampaio, G. Giaccone, R. Zaman, E. Kristosturyan, A. Rajan, L. Ding,
 K.H. Ching, A. Berman, J.B. Oliveira, A.P. Hsu, C.M. Klimavicz, M.J. ladarola, and S.M. Holland.
 2010. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic
 neoplasia. *Blood* 116:4848-4858.
- Busnadiego, I., I.A. Abela, P.M. Frey, D.A. Hofmaenner, T.C. Scheier, R.A. Schuepbach, P.K. Buehler,
 S.D. Brugger, and B.G. Hale. 2022. Critically ill COVID-19 patients with neutralizing autoantibodies
 against type I interferons have increased risk of herpesvirus disease. *PLoS Biol* 20:e3001709.
- 859 Chang, S.E., A. Feng, W. Meng, S.A. Apostolidis, E. Mack, M. Artandi, L. Barman, K. Bennett, S. 860 Chakraborty, I. Chang, P. Cheung, S. Chinthrajah, S. Dhingra, E. Do, A. Finck, A. Gaano, R. 861 Gessner, H.M. Giannini, J. Gonzalez, S. Greib, M. Gundisch, A.R. Hsu, A. Kuo, M. Manohar, R. 862 Mao, I. Neeli, A. Neubauer, O. Oniyide, A.E. Powell, R. Puri, H. Renz, J. Schapiro, P.A. 863 Weidenbacher, R. Wittman, N. Ahuja, H.R. Chung, P. Jagannathan, J.A. James, P.S. Kim, N.J. 864 Meyer, K.C. Nadeau, M. Radic, W.H. Robinson, U. Singh, T.T. Wang, E.J. Wherry, C. Skevaki, E.T. 865 Luning Prak, and P.J. Utz. 2021. New-onset IgG autoantibodies in hospitalized patients with 866 COVID-19. Nat Commun 12:5417.
- Chauvineau-Grenier, A., P. Bastard, A. Servajean, A. Gervais, J. Rosain, E. Jouanguy, A. Cobat, J.L.
 Casanova, and B. Rossi. 2022. Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19
 Deaths in a French Hospital. *Journal of clinical immunology* 42:459-470.
- Credle, J.J., J. Gunn, P. Sangkhapreecha, D.R. Monaco, X.A. Zheng, H.J. Tsai, A. Wilbon, W.R.
 Morgenlander, A. Rastegar, Y. Dong, S. Jayaraman, L. Tosi, B. Parekkadan, A.N. Baer, M.
 Roederer, E.M. Bloch, A.A.R. Tobian, I. Zyskind, J.I. Silverberg, A.Z. Rosenberg, A.L. Cox, T. Lloyd,
 A.L. Mammen, and H. Benjamin Larman. 2022. Unbiased discovery of autoantibodies associated

- with severe COVID-19 via genome-scale self-assembled DNA-barcoded protein libraries. Nat
 Biomed Eng 6:992-1003.
- Buncan, C.J.A., R.E. Randall, and S. Hambleton. 2021. Genetic Lesions of Type I Interferon Signalling in
 Human Antiviral Immunity. *Trends Genet* 37:46-58.
- Bunning, J., S. Blankley, L.T. Hoang, M. Cox, C.M. Graham, P.L. James, C.I. Bloom, D. Chaussabel, J.
 Banchereau, S.J. Brett, M.F. Moffatt, A. O'Garra, P.J.M. Openshaw, and M. Investigators. 2018.
 Progression of whole-blood transcriptional signatures from interferon-induced to neutrophilassociated patterns in severe influenza. *Nat Immunol* 19:625-635.
- EASL, E.A.f.t.S.o.t.L. 2023. EASL Clinical Practice Guidelines on hepatitis delta virus. *J Hepatol* 79:433-460.
- Eto, S., Y. Nukui, M. Tsumura, Y. Nakagama, K. Kashimada, Y. Mizoguchi, T. Utsumi, M. Taniguchi, F.
 Sakura, K. Noma, Y. Yoshida, S. Ohshimo, S. Nagashima, K. Okamoto, A. Endo, K. Imai, H.
 Kanegane, H. Ohnishi, S. Hirata, E. Sugiyama, N. Shime, M. Ito, H. Ohge, Y. Kido, P. Bastard, J.L.
 Casanova, O. Ohara, J. Tanaka, T. Morio, and S. Okada. 2022. Neutralizing Type I Interferon
 Autoantibodies in Japanese Patients with Severe COVID-19. *Journal of clinical immunology*42:1360-1370.
- Frasca, F., M. Scordio, L. Santinelli, L. Gabriele, O. Gandini, A. Criniti, A. Pierangeli, A. Angeloni, C.M.
 Mastroianni, G. d'Ettorre, R.P. Viscidi, G. Antonelli, and C. Scagnolari. 2022. Anti-IFN-alpha/-omega
 neutralizing antibodies from COVID-19 patients correlate with downregulation of IFN response and
 laboratory biomarkers of disease severity. *Eur J Immunol* 52:1120-1128.
- 894 Gervais, A., F. Rovida, M.A. Avanzini, S. Croce, A. Marchal, S.C. Lin, A. Ferrari, C.W. Thorball, O. 895 Constant, T. Le Voyer, Q. Philippot, J. Rosain, M. Angelini, M. Perez Lorenzo, L. Bizien, C. Achille, 896 F. Trespidi, E. Burdino, I. Cassaniti, D. Lilleri, C. Fornara, J.C. Sammartino, D. Cereda, C. Marrocu, 897 A. Piralla, C. Valsecchi, S. Ricagno, P. Cogo, O. Neth, I. Marin-Cruz, M. Pacenti, A. Sinigaglia, M. 898 Trevisan, A. Volpe, A. Marzollo, F. Conti, T. Lazzarotto, A. Pession, P. Viale, J. Fellay, S. 899 Ghirardello, M. Aubart, V. Ghisetti, A. Aiuti, E. Jouanguy, P. Bastard, E. Percivalle, F. Baldanti, A. 900 Puel, M.R. MacDonald, C.M. Rice, G. Rossini, K.O. Murray, Y. Simonin, A. Nagy, L. Barzon, L. 901 Abel, M.S. Diamond, A. Cobat, S.Y. Zhang, J.L. Casanova, and A. Borghesi. 2023. Autoantibodies 902 neutralizing type I IFNs underlie West Nile virus encephalitis in approximately 40% of patients. The 903 Journal of experimental medicine 220:
- Goncalves, D., M. Mezidi, P. Bastard, M. Perret, K. Saker, N. Fabien, R. Pescarmona, C. Lombard, T.
 Walzer, J.L. Casanova, A. Belot, J.C. Richard, and S. Trouillet-Assant. 2021. Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients. *Clin Transl Immunology* 10:e1327.
- Gueler, A., A. Moser, A. Calmy, H.F. Gunthard, E. Bernasconi, H. Furrer, C.A. Fux, M. Battegay, M. Cavassini, P. Vernazza, M. Zwahlen, M. Egger, and S.N.C. Swiss Hiv Cohort Study. 2017. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. *AIDS* 31:427-436.
- Gupta, S., I.P. Tatouli, L.B. Rosen, S. Hasni, I. Alevizos, Z.G. Manna, J. Rivera, C. Jiang, R.M. Siegel,
 S.M. Holland, H.M. Moutsopoulos, and S.K. Browne. 2016. Distinct Functions of Autoantibodies
 Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine
 Autoantibodies in Common Rheumatic Diseases. *Arthritis Rheumatol* 68:1677-1687.
- Hale, B.G. 2023. Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility. *Eur J Immunol* 53:e2250164.
- Hetemaki, I., S. Laakso, H. Valimaa, I. Kleino, E. Kekalainen, O. Makitie, and T.P. Arstila. 2021. Patients
 with autoimmune polyendocrine syndrome type 1 have an increased susceptibility to severe
 herpesvirus infections. *Clin Immunol* 231:108851.
- Höftberger, R., H. Lassmann, T. Berger, and M. Reindl. 2022. Pathogenic autoantibodies in multiple
 sclerosis from a simple idea to a complex concept. *Nature Reviews Neurology* 18:681-688.
- Jorns, C., D. Holzinger, R. Thimme, H.C. Spangenberg, M. Weidmann, J. Rasenack, H.E. Blum, O. Haller,
 and G. Kochs. 2006. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis
 C non-responsive to IFN-alpha. *J Med Virol* 78:74-82.
- Kisand, K., M. Link, A.S. Wolff, A. Meager, L. Tserel, T. Org, A. Murumagi, R. Uibo, N. Willcox, K. Trebusak Podkrajsek, T. Battelino, A. Lobell, O. Kampe, K. Lima, A. Meloni, B. Ergun-Longmire, N.K. Maclaren, J. Perheentupa, K.J. Krohn, H.S. Scott, E.S. Husebye, and P. Peterson. 2008. Interferon autoantibodies associated with AIRE deficiency decrease the expression of IFN-stimulated genes. *Blood* 112:2657-2666.

- Koning, R., P. Bastard, J.L. Casanova, M.C. Brouwer, D. van de Beek, and U.M.C.C.-B.I. with the
 Amsterdam. 2021. Autoantibodies against type I interferons are associated with multi-organ failure
 in COVID-19 patients. *Intensive care medicine* 47:704-706.
- 934 Le Voyer, T., A.V. Parent, X. Liu, A. Cederholm, A. Gervais, J. Rosain, T. Nguyen, M. Perez Lorenzo, E. 935 Rackaityte, D. Rinchai, P. Zhang, L. Bizien, G. Hancioglu, P. Ghillani-Dalbin, J.L. Charuel, Q. 936 Philippot, M.S. Gueye, M.R.L. Maglorius Renkilaraj, M. Ogishi, C. Soudee, M. Migaud, F. 937 Rozenberg, M. Momenilandi, Q. Riller, L. Imberti, O.M. Delmonte, G. Muller, B. Keller, J. Orrego, 938 W.A. Franco Gallego, T. Rubin, M. Emiroglu, N. Parvaneh, D. Eriksson, M. Aranda-Guillen, D.I. 939 Berrios, L. Vong, C.H. Katelaris, P. Mustillo, J. Raedler, J. Bohlen, J. Bengi Celik, C. Astudillo, S. 940 Winter, N.F.-k. Consortium, C.H.G. Effort, C. McLean, A. Guffroy, J.L. DeRisi, D. Yu, C. Miller, Y. 941 Feng, A. Guichard, V. Beziat, J. Bustamante, Q. Pan-Hammarstrom, Y. Zhang, L.B. Rosen, S.M. 942 Holland, M. Bosticardo, H. Kenney, R. Castagnoli, C.A. Slade, K. Boztug, N. Mahlaoui, S. Latour, 943 R.S. Abraham, V. Lougaris, F. Hauck, A. Sediva, F. Atschekzei, G. Sogkas, M.C. Poli, M.A. Slatter, 944 B. Palterer, M.D. Keller, A. Pinzon-Charry, A. Sullivan, L. Droney, D. Suan, M. Wong, A. Kane, H. 945 Hu, C. Ma, H. Grombirikova, P. Ciznar, I. Dalal, N. Aladjidi, M. Hie, E. Lazaro, J. Franco, S. Keles, 946 M. Malphettes, M. Pasquet, M.E. Maccari, A. Meinhardt, A. Ikinciogullari, M. Shahrooei, F. Celmeli, 947 P. Frosk, C.C. Goodnow, P.E. Gray, A. Belot, H.S. Kuehn, S.D. Rosenzweig, M. Miyara, F. 948 Licciardi, A. Servettaz, V. Barlogis, G. Le Guenno, V.M. Herrmann, T. Kuijpers, G. Ducoux, F. 949 Sarrot-Reynauld, C. Schuetz, C. Cunningham-Rundles, F. Rieux-Laucat, S.G. Tangye, C. 950 Sobacchi, R. Doffinger, K. Warnatz, B. Grimbacher, C. Fieschi, L. Berteloot, V.L. Bryant, S. Trouillet 951 Assant, H. Su, B. Neven, L. Abel, Q. Zhang, B. Boisson, A. Cobat, E. Jouanguy, O. Kampe, P. 952 Bastard, C.M. Roifman, N. Landegren, L.D. Notarangelo, M.S. Anderson, J.L. Casanova, and A. 953 Puel. 2023. Autoantibodies against type I IFNs in humans with alternative NF-kappaB pathway 954 deficiency. Nature 623:803-813.
- Liang, Z., X. Dong, Z. Zhang, Q. Zhang, and Y. Zhao. 2022. Age-related thymic involution: Mechanisms and functional impact. *Aging Cell* 21:e13671.
- Liechti, T., C. Kadelka, H. Ebner, N. Friedrich, R.D. Kouyos, H.F. Günthard, and A. Trkola. 2018.
 Development of a high-throughput bead based assay system to measure HIV-1 specific immune signatures in clinical samples. *Journal of immunological methods* 454:48-58.
- Lin, S.C., F.R. Zhao, H. Janova, A. Gervais, S. Rucknagel, K.O. Murray, J.L. Casanova, and M.S.
 Diamond. 2023. Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease. *Nat Commun* 14:5973.
- Lopez, J., M. Mommert, W. Mouton, A. Pizzorno, K. Brengel-Pesce, M. Mezidi, M. Villard, B. Lina, J.C.
 Richard, J.B. Fassier, V. Cheynet, B. Padey, V. Duliere, T. Julien, S. Paul, P. Bastard, A. Belot, A.
 Bal, J.L. Casanova, M. Rosa-Calatrava, F. Morfin, T. Walzer, and S. Trouillet-Assant. 2021. Early
 nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies
 against type I IFNs. *The Journal of experimental medicine* 218:
- 968 Manry, J., P. Bastard, A. Gervais, T. Le Voyer, J. Rosain, Q. Philippot, E. Michailidis, H.H. Hoffmann, S. 969 Eto, M. Garcia-Prat, L. Bizien, A. Parra-Martinez, R. Yang, L. Haljasmagi, M. Migaud, K. 970 Sarekannu, J. Maslovskaja, N. de Prost, Y. Tandjaoui-Lambiotte, C.E. Luvt, B. Amador-Borrero, A. 971 Gaudet, J. Poissy, P. Morel, P. Richard, F. Cognasse, J. Troya, S. Trouillet-Assant, A. Belot, K. 972 Saker, P. Garcon, J.G. Riviere, J.C. Lagier, S. Gentile, L.B. Rosen, E. Shaw, T. Morio, J. Tanaka, 973 D. Dalmau, P.L. Tharaux, D. Sene, A. Stepanian, B. Megarbane, V. Triantafyllia, A. Fekkar, J.R. 974 Heath, J.L. Franco, J.M. Anaya, J. Sole-Violan, L. Imberti, A. Biondi, P. Bonfanti, R. Castagnoli, 975 O.M. Delmonte, Y. Zhang, A.L. Snow, S.M. Holland, C.M. Biggs, M. Moncada-Velez, A.A. Arias, L. 976 Lorenzo, S. Boucherit, D. Anglicheau, A.M. Planas, F. Haerynck, S. Duvlis, T. Ozcelik, S. Keles, 977 A.A. Bousfiha, J. El Bakkouri, C. Ramirez-Santana, S. Paul, Q. Pan-Hammarstrom, L. 978 Hammarstrom, A. Dupont, A. Kurolap, C.N. Metz, A. Aiuti, G. Casari, V. Lampasona, F. Ciceri, L.A. 979 Barreiros, E. Dominguez-Garrido, M. Vidigal, M. Zatz, D. van de Beek, S. Sahanic, I. Tancevski, Y. 980 Stepanovskyy, O. Boyarchuk, Y. Nukui, M. Tsumura, L. Vidaur, S.G. Tangye, S. Burrel, D. Duffy, L. 981 Quintana-Murci, A. Klocperk, N.Y. Kann, A. Shcherbina, Y.L. Lau, D. Leung, M. Coulongeat, J. 982 Marlet, R. Koning, L.F. Reyes, A. Chauvineau-Grenier, F. Venet, G. Monneret, M.C. Nussenzweig, 983 R. Arrestier, I. Boudhabhay, H. Baris-Feldman, D. Hagin, J. Wauters, I. Meyts, A.H. Dyer, S.P. 984 Kennelly, N.M. Bourke, R. Halwani, F.S. Sharif-Askari, K. Dorgham, J. Sallette, S.M. Sedkaoui, S. 985 AlKhater, R. Rigo-Bonnin, F. Morandeira, L. Roussel, D.C. Vinh, C. Erikstrup, A. Condino-Neto, C. 986 Prando, A. Bondarenko, A.N. Spaan, L. Gilardin, J. Fellay, S. Lyonnet, K. Bilguvar, R.P. Lifton, S. 987 Mane, H. Lab, C. Clinicians, C.-S. Clinicians, N.I.R.t.C. Group, N.-C.S. Group, C. Danish, S. Danish

988 Blood Donor, S.C.I.G. St. James's Hospital, C.C.S.G. French, C.-G. Imagine, C. Milieu Interieur, 989 V.C.C. Co, U.M.C.C.-B.I. Amsterdam, C.H.G. Effort, C.-C.-. Group, C. cohort, C.D. Study, H.-C. 990 Cerba, g. Etablissement Francais du Sang Study, M.S. Anderson, B. Boisson, V. Beziat, S.Y. 991 Zhang, E. Andreakos, O. Hermine, A. Pujol, P. Peterson, T.H. Mogensen, L. Rowen, J. Mond, S. 992 Debette, X. de Lamballerie, C. Burdet, L. Bouadma, M. Zins, P. Soler-Palacin, R. Colobran, G. 993 Gorochov, X. Solanich, S. Susen, J. Martinez-Picado, D. Raoult, M. Vasse, P.K. Gregersen, L. 994 Piemonti, C. Rodriguez-Gallego, L.D. Notarangelo, H.C. Su, K. Kisand, S. Okada, A. Puel, E. 995 Jouanguy, C.M. Rice, P. Tiberghien, Q. Zhang, J.L. Casanova, L. Abel, and A. Cobat. 2022. The 996 risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. Proc 997 Natl Acad Sci U S A 119:e2200413119.

- Mathian, A., P. Breillat, K. Dorgham, P. Bastard, C. Charre, R. Lhote, P. Quentric, Q. Moyon, A.A.
 Mariaggi, S. Mouries-Martin, C. Mellot, F. Anna, J. Haroche, F. Cohen-Aubart, D. Sterlin, N. Zahr,
 A. Gervais, T. Le Voyer, L. Bizien, Q. Amiot, M. Pha, M. Hie, F. Chasset, H. Yssel, M. Miyara, P.
 Charneau, P. Ghillani-Dalbin, J.L. Casanova, F. Rozenberg, Z. Amoura, and G. Gorochov. 2022.
 Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with
 systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-alpha. Ann Rheum
 Dis 81:1695-1703.
- Meager, A., K. Visvalingam, P. Peterson, K. Moll, A. Murumagi, K. Krohn, P. Eskelin, J. Perheentupa, E.
 Husebye, Y. Kadota, and N. Willcox. 2006. Anti-interferon autoantibodies in autoimmune
 polyendocrinopathy syndrome type 1. *PLoS Med* 3:e289.
- Meyer, S., M. Woodward, C. Hertel, P. Vlaicu, Y. Haque, J. Karner, A. Macagno, S.C. Onuoha, D. Fishman, H. Peterson, K. Metskula, R. Uibo, K. Jantti, K. Hokynar, A.S.B. Wolff, A.p. collaborative, K. Krohn, A. Ranki, P. Peterson, K. Kisand, and A. Hayday. 2016. AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies. *Cell* 166:582-595.
- 1012 Meyts, I., and J.L. Casanova. 2021. Viral infections in humans and mice with genetic deficiencies of the 1013 type I IFN response pathway. *Eur J Immunol* 51:1039-1061.
- 1014 Mitchell, W.A., P.O. Lang, and R. Aspinall. 2010. Tracing thymic output in older individuals. *Clin Exp* 1015 *Immunol* 161:497-503.
- Mogensen, K.E., P. Daubas, I. Gresser, D. Sereni, and B. Varet. 1981. Patient with circulating antibodies
 to alpha-interferon. *Lancet* 2:1227-1228.
- 1018 Pozzetto, B., K.E. Mogensen, M.G. Tovey, and I. Gresser. 1984. Characteristics of autoantibodies to 1019 human interferon in a patient with varicella-zoster disease. *J Infect Dis* 150:707-713.
- Ramakrishnan, K.A., W. Rae, G. Barcenas-Morales, Y. Gao, R.J. Pengelly, S.V. Patel, D.S. Kumararatne,
 S. Ennis, R. Doffinger, S.N. Faust, and A.P. Williams. 2018. Anticytokine autoantibodies in a patient
 with a heterozygous NFKB2 mutation. *J Allergy Clin Immunol* 141:1479-1482 e1476.
- 1023Ronnblom, L.E., E.T. Janson, A. Perers, K.E. Oberg, and G.V. Alm. 1992. Characterization of anti-
interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. *Clin Exp*
Immunol 89:330-335.
- 1026 Roszkiewicz, J., and E. Smolewska. 2016. Kaleidoscope of autoimmune diseases in HIV infection. 1027 *Rheumatol Int* 36:1481-1491.
- Scherrer, A.U., A. Traytel, D.L. Braun, A. Calmy, M. Battegay, M. Cavassini, H. Furrer, P. Schmid, E. Bernasconi, M. Stoeckle, C. Kahlert, A. Trkola, R.D. Kouyos, P. Tarr, C. Marzolini, G. Wandeler, J. Fellay, H. Bucher, S. Yerly, F. Suter, H. Hirsch, M. Huber, G. Dollenmaier, M. Perreau, G. Martinetti, A. Rauch, H.F. Gunthard, and H.I.V.C.S. Swiss. 2022. Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). *Int J Epidemiol* 51:33-34j.
- Scordio, M., F. Frasca, L. Santinelli, L. Sorrentino, A. Pierangeli, O. Turriziani, C.M. Mastroianni, G.
 Antonelli, R.P. Viscidi, G. d'Ettorre, and C. Scagnolari. 2022. High frequency of neutralizing
 antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19. *Clin Immunol* 241:109068.
- Sjogren, T., E. Bratland, E.C. Royrvik, M.A. Grytaas, A. Benneche, P.M. Knappskog, O. Kampe, B.E.
 Oftedal, E.S. Husebye, and A.S.B. Wolff. 2022. Screening patients with autoimmune endocrine
 disorders for cytokine autoantibodies reveals monogenic immune deficiencies. *J Autoimmun* 133:102917.
- Solanich, X., R. Rigo-Bonnin, V.D. Gumucio, P. Bastard, J. Rosain, Q. Philippot, X.L. Perez-Fernandez, M.P. Fuset-Cabanes, M.A. Gordillo-Benitez, G. Suarez-Cuartin, E. Boza-Hernandez, A. Riera-Mestre, A. Parra-Martinez, R. Colobran, A. Antoli, S. Navarro, G. Rocamora-Blanch, M. Framil, L. Calatayud, X. Corbella, J.L. Casanova, F. Morandeira, and J. Sabater-Riera. 2021. Pre-existing

- 1045Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-191046Patients Admitted to Intensive Care in Barcelona. Journal of clinical immunology 41:1733-1744.
- Steels, S., J. Van Elslande, C.-S.G. Leuven, P. De Munter, and X. Bossuyt. 2022. Transient Increase of
 Pre-existing Anti-IFN-alpha2 Antibodies Induced by SARS-CoV-2 Infection. *Journal of clinical immunology* 42:742-745.
- 1050 Stertz, S., and B.G. Hale. 2021. Interferon system deficiencies exacerbating severe pandemic virus 1051 infections. *Trends Microbiol* 29:973-982.
- Sundqvist, E., T. Bergström, H. Daialhosein, M. Nyström, P. Sundström, J. Hillert, L. Alfredsson, I. Kockum, and T. Olsson. 2014. Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. *Multiple Sclerosis Journal* 20:165-173.
- 1055Troya, J., P. Bastard, L. Planas-Serra, P. Ryan, M. Ruiz, M. de Carranza, J. Torres, A. Martinez, L. Abel,1056J.L. Casanova, and A. Pujol. 2021. Neutralizing Autoantibodies to Type I IFNs in >10% of Patients1057with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain. Journal of clinical immunology105841:914-922.
- Trutschel, D., P. Bost, X. Mariette, V. Bondet, A. Llibre, C. Posseme, B. Charbit, C.W. Thorball, R. Jonsson, C.J. Lessard, R. Felten, W.F. Ng, L. Chatenoud, H. Dumortier, J. Sibilia, J. Fellay, K.A. Brokstad, S. Appel, J.R. Tarn, L. Quintana-Murci, M. Mingueneau, N. Meyer, D. Duffy, B. Schwikowski, J.E. Gottenberg, A.s.i. Milieu Interieur Consortium, and N. Consortium. 2022.
 Variability of Primary Sjogren's Syndrome Is Driven by Interferon-alpha and Interferon-alpha Blood Levels Are Associated With the Class II HLA-DQ Locus. *Arthritis Rheumatol* 74:1991-2002.
- 1065 van der Wijst, M.G.P., S.E. Vazquez, G.C. Hartoularos, P. Bastard, T. Grant, R. Bueno, D.S. Lee, J.R. 1066 Greenland, Y. Sun, R. Perez, A. Ogorodnikov, A. Ward, S.A. Mann, K.L. Lynch, C. Yun, D.V. Havlir, 1067 G. Chamie, C. Marquez, B. Greenhouse, M.S. Lionakis, P.J. Norris, L.J. Dumont, K. Kelly, P. 1068 Zhang, Q. Zhang, A. Gervais, T. Le Voyer, A. Whatley, Y. Si, A. Byrne, A.J. Combes, A.A. Rao, 1069 Y.S. Song, G.K. Fragiadakis, K. Kangelaris, C.S. Calfee, D.J. Erle, C. Hendrickson, M.F. Krummel, 1070 P.G. Woodruff, C.R. Langelier, J.L. Casanova, J.L. Derisi, M.S. Anderson, C.J. Ye, and U.C. 1071 consortium. 2021. Type I interferon autoantibodies are associated with systemic immune alterations 1072 in patients with COVID-19. Science translational medicine 13:eabh2624.
- 1073
 1074
 1074
 1074
 1075
 1075
 1076
 1076
 1076
 1077
 1077
 Vandoren, R., M. Boeren, J. Schippers, E. Bartholomeus, K. Mullan, N. Michels, O. Aerts, J. Leysen, A. Bervoets, J. Lambert, E. Leuridan, J. Wens, K. Peeters, M.P. Emonds, H. Jansens, J.L. Casanova, P. Bastard, A. Suls, V. Van Tendeloo, P. Ponsaerts, P. Delputte, B. Ogunjimi, K. Laukens, and P. Meysman. 2024. Unravelling the immune signature of herpes zoster: Insights into pathophysiology and the HLA risk profile. *J Infect Dis*
- 1078 Walter, J.E., L.B. Rosen, K. Csomos, J.M. Rosenberg, D. Mathew, M. Keszei, B. Ujhazi, K. Chen, Y.N. 1079 Lee, I. Tirosh, K. Dobbs, W. Al-Herz, M.J. Cowan, J. Puck, J.J. Bleesing, M.S. Grimley, H. Malech, 1080 S.S. De Ravin, A.R. Gennery, R.S. Abraham, A.Y. Joshi, T.G. Boyce, M.J. Butte, K.C. Nadeau, I. 1081 Balboni, K.E. Sullivan, J. Akhter, M. Adeli, R.A. El-Feky, D.H. El-Ghoneimy, G. Dbaibo, R. Wakim, 1082 C. Azzari, P. Palma, C. Cancrini, K. Capuder, A. Condino-Neto, B.T. Costa-Carvalho, J.B. Oliveira, 1083 C. Roifman, D. Buchbinder, A. Kumanovics, J.L. Franco, T. Niehues, C. Schuetz, T. Kuijpers, C. 1084 Yee, J. Chou, M.J. Masaad, R. Geha, G. Uzel, R. Gelman, S.M. Holland, M. Recher, P.J. Utz, S.K. 1085 Browne, and L.D. Notarangelo. 2015. Broad-spectrum antibodies against self-antigens and 1086 cytokines in RAG deficiency. J Clin Invest 125:4135-4148.
- Wang, E.Y., T. Mao, J. Klein, Y. Dai, J.D. Huck, J.R. Jaycox, F. Liu, T. Zhou, B. Israelow, P. Wong, A. Coppi, C. Lucas, J. Silva, J.E. Oh, E. Song, E.S. Perotti, N.S. Zheng, S. Fischer, M. Campbell, J.B. Fournier, A.L. Wyllie, C.B.F. Vogels, I.M. Ott, C.C. Kalinich, M.E. Petrone, A.E. Watkins, I.T. Yale, C. Dela Cruz, S.F. Farhadian, W.L. Schulz, S. Ma, N.D. Grubaugh, A.I. Ko, A. Iwasaki, and A.M. Ring. 2021. Diverse functional autoantibodies in patients with COVID-19. *Nature* 595:283-288.
- Waubant, E., E.M. Mowry, L. Krupp, T. Chitnis, E.A. Yeh, N. Kuntz, J. Ness, D. Chabas, J. Strober, J.
 McDonald, A. Belman, M. Milazzo, M. Gorman, B. Weinstock-Guttman, M. Rodriguez, J.R.
 Oksenberg, J.A. James, and U.S.P.M. Network. 2011. Common viruses associated with lower
 pediatric multiple sclerosis risk. *Neurology* 76:1989-1995.
- 1096 Zandman-Goddard, G., and Y. Shoenfeld. 2002. HIV and autoimmunity. Autoimmun Rev 1:329-337.
- Zhang, Q., A. Pizzorno, L. Miorin, P. Bastard, A. Gervais, T. Le Voyer, L. Bizien, J. Manry, J. Rosain, Q.
 Philippot, K. Goavec, B. Padey, A. Cupic, E. Laurent, K. Saker, M. Vanker, K. Sarekannu, C.H.G.
 Effort, G. Etablissement Francais du Sang Study, C. Constances, C.D. Study, G. Cerba
 HealthCare, G. Lyon Antigrippe Working, R.I.W. Group, T. Garcia-Salum, M. Ferres, N. Le Corre, J.
 Sanchez-Cespedes, M. Balsera-Manzanero, J. Carratala, P. Retamar-Gentil, G. Abelenda-Alonso,

1102 A. Valiente, P. Tiberghien, M. Zins, S. Debette, I. Meyts, F. Haerynck, R. Castagnoli, L.D. 1103 Notarangelo, L.I. Gonzalez-Granado, N. Dominguez-Pinilla, E. Andreakos, V. Triantafyllia, C. 1104 Rodriguez-Gallego, J. Sole-Violan, J.J. Ruiz-Hernandez, F. Rodriguez de Castro, J. Ferreres, M. 1105 Briones, J. Wauters, L. Vanderbeke, S. Feys, C.Y. Kuo, W.T. Lei, C.L. Ku, G. Tal, A. Etzioni, S. 1106 Hanna, T. Fournet, J.S. Casalegno, G. Queromes, L. Argaud, E. Javouhey, M. Rosa-Calatrava, E. 1107 Cordero, T. Aydillo, R.A. Medina, K. Kisand, A. Puel, E. Jouanguy, L. Abel, A. Cobat, S. Trouillet-1108 Assant, A. Garcia-Sastre, and J.L. Casanova. 2022. Autoantibodies against type I IFNs in patients 1109 with critical influenza pneumonia. J Exp Med 219:

1110

1111

FIGURE LEGENDS

1112

1113 Figure 1. Identification and characterization of anti-IFN-I autoAbs in an aging, 1114 longitudinally-sampled, infectious disease patient cohort. (A-C) Validated screening results 1115 for presence of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG in plasma samples derived from 1876 1116 unique patients enrolled in the SHCS and aged >65 years at the time of sampling. Median 1117 Fluorescence Intensity (MFI) Fold Change (FC) of IgG values obtained from IFN-I-coated beads 1118 relative to the MFI of IgG values obtained from empty beads is shown, normalized to the cohort 1119 means for each IFN-I. All individual patient samples are shown (circles), with samples 1120 considered positive after subsequent analysis of longitudinal samples colored (see Methods for 1121 thresholds). Solid colored circles represent plasma samples that also neutralized the respective 1122 IFN-I in subsequent assays. Numbers and percentage of positive patients (neutralizing and non-1123 neutralizing IgG) are indicated for each anti-IFN-I IgG. (B) Pairwise representation of the data 1124 shown in (A) comparing the indicated combinations of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG 1125 found in each patient plasma sample. (C) Venn diagram analysis of the 35 anti-IFN-I autoAb-1126 positive patients highlighting the anti-IFN-I autoAb specificities observed for neutralizing and 1127 non-neutralizing IgG. Percentages refer to the entire sub-cohort (1876 patients). The asterisk 1128 denotes the inclusion of a single patient found to possess binding and neutralizing anti-IFNa2 1129 IgG, as well as binding and non-neutralizing anti-IFN ω IgG. (D-E) Plasma samples from anti-1130 IFN-I autoAb-positive patients were analyzed to determine relative levels (%) of each of the four 1131 IgG subclasses targeting IFN-Is. (D) Patient-level analysis shown as a heat-map, where white

blocks indicate no anti-IFN-I IgG subclass was detected, and slashed blocks indicate IgG subclass was not determined. (E) IgG subclass analysis in all patients for each IFN-I. Statistical analysis was performed using a one-way ANOVA with Tukey's multiple comparison (single pooled variance). *P* values and significance are indicated (ns = non-significant).

1136

1137 Figure 2. High-resolution longitudinal analysis of anti-IFN-I autoAb development over 1138 decades. Semiannually biobanked plasma samples available for all 35 anti-IFN-I autoAb-1139 positive patients (and several negative patients) were analyzed for anti-IFN α 2, anti-IFN β and 1140 anti-IFN ω IgG levels, as well as for IFN α 2, IFN β or IFN ω neutralization capacity. (A) Frequency 1141 of ages (years) where each anti-IFN-I autoAb was first detected. The median age of first 1142 detection (induction) is noted. (B) MFI FC values for each anti-IFNa2, anti-IFNB and anti-IFNw 1143 IgG in each patient comparing relative levels between the first timepoint where anti-IFN-I 1144 autoAbs were detected and the last available timepoint sampled. Statistical analysis was 1145 performed using a Wilcoxon matched-pairs signed rank test. P values and significance are 1146 indicated (ns = non-significant). (C-I) Patient-level representation of anti-IFN α 2, anti-IFN β and 1147 anti-IFN ω IgG levels (MFI FC), as well as IFN α 2, IFN β or IFN ω neutralization (inhibition of IFN-1148 induced Luciferase (Luc) activity) at 3 different doses (see Methods), for all available longitudinal 1149 samples plotted as a function of patient age (years). Colored circles represent samples 1150 considered positive for either binding IgG or neutralization (see Methods for thresholds). 1151 Triangles in neutralization plots represent negative controls. In (C-I), individual patients are 1152 grouped according to the types of IFN-I to which they possess binding and neutralizing IgG 1153 (indicated at the top of each panel, together with the n/35 patients who have a similar 1154 phenotype). The patient in (I) is a negative patient who never developed anti-IFN-I autoAbs. See 1155 also Supplementary Figures 1 and 2.

1156

1157 Figure 3. Neutralizing anti-IFNα2 autoAbs are associated with compromised baseline IFN-

1158 stimulated gene (ISG) levels. (A) Area under the curve (AUC) values for clinically determined 1159 cell compositions in whole blood (as indicated) in 16 patients who developed neutralizing anti-1160 IFNa2 autoAbs. Existing clinical cell titers were obtained for each patient from the SHCS, and 1161 AUC values were determined from all available data up to 1 year before (Pre) or 1 year after 1162 (Post) the timepoint where anti-IFNα2 autoAbs were first detected. Statistical analysis was 1163 performed using a paired Wilcoxon signed rank test. P values are indicated. (B-C) RT-qPCR 1164 analysis of the indicated ISGs in PBMCs from 13 patients who developed neutralizing anti-IFNa 1165 autoAbs (B) or 13 age-matched control patients who never developed anti-IFN-I autoAbs (C). 1166 Data shown for each patient represent mean percentage changes in expression of the indicated 1167 ISG relative to the first timepoint (i.e. samples taken before development of anti-IFNa autoAbs 1168 for (B), or to the equivalent timepoint for (C)). Statistical significance of changes across the 13 1169 patients was determined based on the original Δ Ct values (normalized to GAPDH) using a 1170 Mann-Whitney U test. P values and significance are indicated (ns = non-significant).

1171

1172 Figure 4. Prior infections and immune factors influence the development of anti-IFN-I 1173 autoAbs. (A-C) Mosaic plots comparing the SHCS recorded incidence of prior CMV positivity 1174 (A), prior herpes zoster diagnosis (B), or prior ANA test positivity (C) between patients who 1175 developed anti-IFN-I autoAbs and matched control patients who did not. In (A) and (B), only 1176 patients with complete data for the indicated parameter were included (therefore n differs slightly 1177 with that in Supplementary Table 3). In (C), only patients who were tested are included. (D) 1178 Screening results for the presence of 19 different anti-autoantigen IgGs in plasma samples 1179 derived from 22 anti-IFN-I autoAb positive (Pos) patients and 22 age-matched negative control 1180 (Neg) patients who were confirmed to have never developed anti-IFN-I autoAbs. Two samples 1181 per patient were tested, which were the two samples immediately preceding first detection of 1182 anti-IFN-I autoAbs (for the positive patients; typically 6 and 12 months before) or age-matched

1183 timepoints for the negative patients. MFI FC IgG values obtained from the indicated autoantigen-1184 coated beads are shown relative to the MFI of IgG values obtained from empty beads 1185 normalized to the negative patient mean for each autoantigen. All patient samples are shown 1186 (circles). Patient plasmas exhibiting normalized MFI values >5 SDs above the mean MFIs 1187 obtained from the negative patient samples (dotted lines) were considered positive for the 1188 specific anti-autoantigen IgG and are colored and labelled. (E) Mosaic plot analysis of the data in 1189 (D). For panels (A) and (B) statistical analyses were performed using conditional-logistic 1190 regression (taking into account the matched nature of the data) and likelihood-ratio tests, for 1191 panel (C) statistical analysis was performed using Fisher's Exact Test for Count Data (as the 1192 routine ANA data were not available for matched pairs of cases and controls), and for panel (E) 1193 statistical analysis was performed using Exact McNemar test (as this takes into account both the 1194 paired nature of the data and the absence of events in one group). P values are indicated.

1195

Figure 5. Therapeutic IFNa likely triggered development and lifelong persistence of 1196 1197 neutralizing anti-IFN α autoAbs in an individual with pre-existing autoimmunity. (A) 1198 Representation of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG levels (MFI FC), as well as IFN α 2 1199 neutralization (inhibition of IFN-induced Luciferase (Luc) activity) at 3 different doses (see 1200 Methods), for all available longitudinal samples from patient P7 (who was treated therapeutically 1201 with IFN α 2) plotted as a function of patient age (years). (B) Validated screening results for the 1202 presence of anti-IFNa2 IgG in plasma samples derived from 300 unique patients enrolled in the 1203 SHCS who were treated with IFN α 2. Two samples per patient were assayed: the first sample 1204 available after IFNa treatment (typically around 6 months), and the last sample available (most 1205 recent: typically 10-20 years later). MFI FC values obtained from IFNα2-coated beads relative to 1206 the MFI of values obtained from empty beads is shown, normalized to the cohort mean. All 1207 individual patient samples are shown (circles), with samples considered positive after 1208 subsequent analysis of longitudinal samples colored (see Methods for thresholds). Solid colored

1209 circles represent plasma samples that also neutralized IFNa when assayed. Positive patient 1210 samples are labeled. (C-E) Representation of data similar to (A), but for all available longitudinal 1211 samples from the indicated patients who had also been treated therapeutically with IFN $\alpha 2$. (F) 1212 Heatmap representation of screening results for the presence of 19 different anti-autoantigen 1213 IgGs in plasma samples derived from 8 patients who had been treated therapeutically with 1214 IFN α 2. Two samples per patient were tested, which were the two samples immediately 1215 preceding the start of IFNa2 treatment (typically 6 and 12 months before), as well as 1216 immediately preceding first detection of anti-IFN-I autoAbs (for newly-identified patient *P36). 1217 MFI FC IgG values obtained from the indicated autoantigen-coated beads are shown relative to 1218 the MFI of IgG values obtained from empty beads normalized to the means of controls shown in 1219 Fig. 4. Patient plasmas exhibiting normalized MFI values >5 SDs above the mean MFIs obtained 1220 from the controls shown in Fig. 4 were considered positive for the specific anti-autoantigen IgG 1221 and are colored. Note that the samples for P7 are the same as shown in Fig. 4 as the start of 1222 IFNa2 treatment coincided with first detection of anti-IFN-I autoAbs. (G) Representation of anti-1223 IFN α 2 (from panel A) and anti- β 2-GPI IgG levels (MFI FC), in selected longitudinal samples from 1224 patient P7 plotted as a function of patient age (years). In panels (A-E) and (G), colored circles 1225 represent samples considered positive for either binding IgG or neutralization (see Methods for 1226 thresholds). Triangles in neutralization plots represent negative controls. Blue shading indicates 1227 the period of time when each patient underwent IFNa2 treatment.

1228

Supplementary Figure 1. High-resolution longitudinal analysis of anti-IFN-I autoAb development over decades (continued from Figure 2). Semiannually biobanked plasma samples available for all 35 anti-IFN-I autoAb-positive patients were analyzed for anti-IFN α 2, anti-IFN β and anti-IFN ω IgG levels, as well as for IFN α 2, IFN β or IFN ω neutralization capacity. (A-E) Patient-level representation of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG levels (MFI FC), as well as IFN α 2, IFN β or IFN ω neutralization (inhibition of IFN-induced Luciferase (Luc) activity)

at 3 different doses (see Methods), for all available longitudinal samples plotted as a function of patient age (years). Colored circles represent samples considered positive for either binding IgG or neutralization (see Methods for thresholds). Triangles in neutralization plots represent negative controls. In all panels, individual patients are grouped according to the types of IFN-I to which they possess binding and neutralizing IgG (indicated at the top of each panel, together with the n/35 patients who have a similar phenotype).

1241

Supplementary Figure 2. High-resolution longitudinal analysis of anti-IFN-I autoAbs over decades in negative patients (continued from Figure 2). Semiannually biobanked plasma samples available for 5 patients who were negative for anti-IFN-I autoAbs in initial screenings were analyzed for anti-IFN α 2, anti-IFN β and anti-IFN ω IgG. Each panel is a patient-level representation of anti-IFN α 2, anti-IFN β and anti-IFN ω IgG levels (MFI FC) plotted as a function of patient age (years). All samples were considered negative for binding IgG based on established thresholds (see Methods for details).









